Johannes Oldenburg

Q: What Schools Are Affiliated With Johannes Oldenburg

Johannes Oldenburg is affiliated with the following schools: University of Lübeck, University of Göttingen, Johns Hopkins University, University of Würzburg, University of Bonn

Johannes Oldenburg's AcademicInfluence.com Rankings

Johannes Oldenburg

Physics

#4974

World Rank

#6734

Historical Rank

Biophysics

#169

World Rank

#179

Historical Rank

physics Degrees

Download Badge

Physics

Why Is Johannes Oldenburg Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Johannes Oldenburg's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2 (2004) (1140)
Emicizumab Prophylaxis in Hemophilia A with Inhibitors (2017) (599)
Emicizumab Prophylaxis in Patients Who Have Hemophilia A without Inhibitors (2018) (391)
Haemophilia A: Mutation Type Determines Risk of Inhibitor Formation (1995) (350)
The Genetic Basis of Resistance to Anticoagulants in Rodents (2005) (319)
F8 gene mutation type and inhibitor development in patients with severe hemophilia A: systematic review and meta-analysis. (2012) (304)
Intensity of factor VIII treatment and inhibitor development in children with severe hemophilia A: the RODIN study. (2013) (283)
Polymorphisms in the IL10 but not in the IL1beta and IL4 genes are associated with inhibitor development in patients with hemophilia A. (2006) (282)
VKORC1 haplotypes and their impact on the inter-individual and inter-ethnical variability of oral anticoagulation (2005) (280)
Gender specific differences in levels of DNA methylation at selected loci from human total blood: a tendency toward higher methylation levels in males (2007) (261)
Optimal treatment strategies for hemophilia: achievements and limitations of current prophylactic regimens. (2015) (257)
Genetic risk factors for inhibitors to factors VIII and IX (2006) (243)
Polymorphisms in the TNFA gene and the risk of inhibitor development in patients with hemophilia A. (2006) (234)
Immune Tolerance for the Treatment of Factor VIII Inhibitors ‐ Twenty Years' ‘Bonn Protocol’ (1996) (232)
Kinase domain mutations of BCR-ABL frequently precede imatinib-based therapy and give rise to relapse in patients with de novo Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL). (2007) (225)
HLA Genotype of Patients with Severe Haemophilia A due to Intron 22 Inversion with and without Inhibitors of Factor VIII (1997) (202)
Haemophilia A: from mutation analysis to new therapies (2005) (193)
A multicenter, open-label, phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors. (2019) (190)
Factor VIII gene (F8) mutation and risk of inhibitor development in nonsevere hemophilia A. (2013) (189)
Inhibitor development in correlation to factor VIII genotypes (2002) (178)
Diagnosis and Management of Vaccine-Related Thrombosis following AstraZeneca COVID-19 Vaccination: Guidance Statement from the GTH (2021) (176)
Polymorphisms in the CTLA‐4 gene and inhibitor development in patients with severe hemophilia A (2007) (175)
Impact of polymorphisms of the major histocompatibility complex class II, interleukin‐10, tumor necrosis factor‐α and cytotoxic T‐lymphocyte antigen‐4 genes on inhibitor development in severe hemophilia A (2009) (173)
Immunosuppression may lead to progression of hepatitis C virus-associated liver disease in hemophiliacs coinfected with HIV. (1996) (168)
Environmental and genetic factors influencing inhibitor development. (2004) (165)
Interethnic variability of warfarin maintenance requirement is explained by VKORC1 genotype in an Asian population (2006) (160)
Distinct characteristics of antibody responses against factor VIII in healthy individuals and in different cohorts of hemophilia A patients. (2013) (157)
Patient Blood Management is Associated With a Substantial Reduction of Red Blood Cell Utilization and Safe for Patient's Outcome: A Prospective, Multicenter Cohort Study With a Noninferiority Design (2016) (156)
Interferon-lambda serum levels in hepatitis C. (2011) (155)
Recombinant long-acting glycoPEGylated factor IX in hemophilia B: a multinational randomized phase 3 trial. (2014) (155)
Characterization of the factor VIII defect in 147 patients with sporadic hemophilia A: family studies indicate a mutation type-dependent sex ratio of mutation frequencies. (1996) (152)
Long-acting recombinant coagulation factor IX albumin fusion protein (rIX-FP) in hemophilia B: results of a phase 3 trial. (2016) (149)
Novel mutations in the VKORC1 gene of wild rats and mice – a response to 50 years of selection pressure by warfarin? (2009) (146)
Somatic mosaicism in hemophilia A: a fairly common event. (2001) (145)
Maternal alleles acquiring paternal methylation patterns in biparental complete hydatidiform moles. (2003) (141)
Molecular characterization of mild-to-moderate hemophilia A: detection of the mutation in 25 of 29 patients by denaturing gradient gel electrophoresis. (1991) (133)
International Registry on Factor XIII Deficiency: A basis formed mostly on European data (2007) (129)
VKORC1: molecular target of coumarins (2007) (125)
A critical appraisal of one‐stage and chromogenic assays of factor VIII activity (2016) (117)
Recombinant factor XIII: a safe and novel treatment for congenital factor XIII deficiency. (2010) (115)
Osteoporosis in haemophilia – an underestimated comorbidity? (2007) (114)
The PNPLA3 rs738409 148M/M Genotype Is a Risk Factor for Liver Cancer in Alcoholic Cirrhosis but Shows No or Weak Association in Hepatitis C Cirrhosis (2011) (113)
Vitamin K epoxide reductase complex subunit 1 (VKORC1): the key protein of the vitamin K cycle. (2006) (110)
Tr1 and naturally occurring regulatory T cells induce IgG4 in B cells through GITR/GITR‐L interaction, IL‐10 and TGF‐β (2008) (109)
Molecular basis of haemophilia A (2004) (109)
Inhibitor treatment in haemophilias A and B: summary statement for the 2006 international consensus conference (2006) (107)
Human Plasmacytoid Dendritic Cells Support Th17 Cell Effector Function in Response to TLR7 Ligation (2009) (107)
Induction of Immune Tolerance in Haemophilia A Inhibitor Patients by the ‘Bonn Protocol’: Predictive Parameter for Therapy Duration and Outcome (1999) (107)
Site-directed mutagenesis of coumarin-type anticoagulant-sensitive VKORC1 (2005) (106)
Congenital Deficiency of Vitamin K Dependent Coagulation Factors in Two Families Presents as a Genetic Defect of the Vitamin K-Epoxide-Reductase-Complex (2000) (106)
Affinity of FVIII-specific antibodies reveals major differences between neutralizing and nonneutralizing antibodies in humans. (2015) (101)
Deficiencies of antithrombin, protein C and protein S – Practical experience in genetic analysis of a large patient cohort (2012) (100)
The polygenic nature of inhibitors in hemophilia A: results from the Hemophilia Inhibitor Genetics Study (HIGS) Combined Cohort. (2013) (99)
The Malmö International Brother Study (MIBS). Genetic defects and inhibitor development in siblings with severe hemophilia A. (2005) (99)
Thirteen novel VKORC1 mutations associated with oral anticoagulant resistance: insights into improved patient diagnosis and treatment (2011) (98)
The vitamin K cycle. (2008) (98)
Inhibitor development in previously untreated patients with hemophilia A: a prospective long-term follow-up comparing plasma-derived and recombinant products. (2002) (97)
The Mystery of Antibodies Against Polyethylene Glycol (PEG) - What do we Know? (2016) (94)
Risk factors for inhibitor development in hemophilia A. (2000) (93)
Molecular basis of antithrombin deficiency (2011) (93)
Human Vitamin K 2,3-Epoxide Reductase Complex Subunit 1-like 1 (VKORC1L1) Mediates Vitamin K-dependent Intracellular Antioxidant Function* (2011) (93)
Missense mutations at ALA‐10 in the factor IX propeptide: an insignificant variant in normal life but a decisive cause of bleeding during oral anticoagulant therapy (1997) (91)
Current pharmacogenetic developments in oral anticoagulation therapy: The influence of variant VKORC1 and CYP2C9 alleles (2007) (90)
Evaluation of DHPLC in the analysis of hemophilia A. (2001) (89)
Expression and characterization of von Willebrand factor dimerization defects in different types of von Willebrand disease. (2001) (89)
Emicizumab Prophylaxis in Hemophilia A with Inhibitors. (2017) (88)
Clinical evaluation of glycoPEGylated recombinant FVIII: Efficacy and safety in severe haemophilia A (2016) (88)
Long-term outcomes with emicizumab prophylaxis for hemophilia A with/without FVIII inhibitors from the HAVEN 1-4 studies. (2020) (87)
Results of a Screening for von Willebrand Disease Type 2N in Patients with Suspected Haemophilia A or von Willebrand Disease Type 1 (1996) (86)
Subcutaneous concizumab prophylaxis in hemophilia A and hemophilia A/B with inhibitors: Phase 2 trial results. (2019) (85)
Methylation at Global LINE-1 Repeats in Human Blood Are Affected by Gender but Not by Age or Natural Hormone Cycles (2011) (83)
Coagulopathy in COVID-19 and Its Implication for Safe and Efficacious Thromboprophylaxis (2020) (83)
Acute hepatitis A in haemophiliacs (1992) (83)
Gain‐of‐Function Mutation in STIM1 (P.R304W) Is Associated with Stormorken Syndrome (2014) (78)
Analysis of mRNA in hemophilia A patients with undetectable mutations reveals normal splicing in the factor VIII gene (2005) (78)
Homozygosity mapping of a second gene locus for hereditary combined deficiency of vitamin K-dependent clotting factors to the centromeric region of chromosome 16. (2002) (77)
Mutational spectrum of the C1INH (SERPING1) gene in patients with hereditary angioedema (2008) (77)
Compound heterozygous mutations in the γ‐glutamyl carboxylase gene cause combined deficiency of all vitamin K‐dependent blood coagulation factors (2004) (71)
Profiling of active thrombin in human blood by supramolecular complexes. (2011) (71)
A rapid, quantitative, non-radioactive bisulfite-SNuPE- IP RP HPLC assay for methylation analysis at specific CpG sites. (2002) (71)
Efficacy and safety of rVIII-SingleChain: results of a phase 1/3 multicenter clinical trial in severe hemophilia A. (2016) (71)
Haemophilia care then, now and in the future (2009) (71)
Protection From Type 1 Diabetes by Vitamin D Receptor Haplotypes (2006) (69)
Defining Severity of Hemophilia: More than Factor Levels (2013) (68)
VKORC1 deficiency in mice causes early postnatal lethality due to severe bleeding (2009) (68)
Characterization of mutations within the factor VIII gene of 73 unrelated mild and moderate haemophiliacs (1995) (66)
Deep intronic ‘mutations’ cause hemophilia A: application of next generation sequencing in patients without detectable mutation in F8 cDNA (2013) (66)
Acute HIV-1 Infection in Patients with Hemophilia B Treated with β-Propiolactone-UV-lnactivated Clotting Factor (1990) (66)
Association between Anxiety and Factors of Coagulation and Fibrinolysis (2008) (66)
Small Deletion/Insertion Mutations within Poly-A Runs of the Factor VIII Gene Mitigate the Severe Haemophilia A Phenotype (1998) (65)
Vitamin K-dependent coagulation factors deficiency. (2009) (63)
Inhibitors in haemophilia: pathophysiology (2004) (62)
Haemophilia A mutations in patients with non-severe phenotype associated with a discrepancy between one-stage and chromogenic factor VIII activity assays (2014) (61)
Molecular mechanisms underlying hemophilia A phenotype in seven females (2009) (60)
The changing face of immune tolerance induction in haemophilia A with the advent of emicizumab (2019) (60)
HAVEN 2 Updated Analysis: Multicenter, Open-Label, Phase 3 Study to Evaluate Efficacy, Safety and Pharmacokinetics of Subcutaneous Administration of Emicizumab Prophylaxis in Pediatric Patients with Hemophilia A with Inhibitors (2017) (58)
DNA methylation signature in peripheral blood reveals distinct characteristics of human X chromosome numerical aberrations (2015) (57)
Inhibitor Development in Patients with Hemophilia A after Continuous Infusion of FVIII Concentrates (2005) (57)
A systematic search for DNA methyltransferase polymorphisms reveals a rare DNMT3L variant associated with subtelomeric hypomethylation. (2009) (56)
Long-term therapy and on-demand treatment of children and adolescents with severe haemophilia A: 12 years of experience. (1992) (56)
Genetic defects and inhibitor development in siblings with severe hemophilia (2005) (56)
Association between phenotype and genotype in carriers of haemophilia A (2011) (55)
Coagulation factor XIII deficiency (2014) (55)
Target plasma factor levels for personalized treatment in haemophilia: a Delphi consensus statement (2017) (54)
An update of the mutation profile of Factor 13 A and B genes. (2011) (54)
De novo factor VIII gene intron 22 inversion in a female carrier presents as a somatic mosaicism. (2000) (54)
New Insight into the Molecular Basis of Hemophilia A (2006) (54)
The effect of emicizumab prophylaxis on health‐related outcomes in persons with haemophilia A with inhibitors: HAVEN 1 Study (2018) (54)
Controlled, cross-sectional MRI evaluation of joint status in severe haemophilia A patients treated with prophylaxis vs. on demand (2014) (54)
Primary and rescue immune tolerance induction in children and adults: a multicentre international study with a VWF‐containing plasma‐derived FVIII concentrate (2014) (54)
An exosite-specific ssDNA aptamer inhibits the anticoagulant functions of activated protein C and enhances inhibition by protein C inhibitor. (2009) (53)
Search for intrafamilial transmission of hepatitis C virus in hemophilia patients. (1993) (53)
Novel products for haemostasis – current status (2014) (52)
European retrospective study of real‐life haemophilia treatment (2017) (52)
Detection of large duplications within the factor VIII gene by MLPA 1 (2008) (51)
Nonacog beta pegol (N9-GP) in haemophilia B: A multinational phase III safety and efficacy extension trial (paradigm™4). (2016) (51)
Haemophilia patients’ unmet needs and their expectations of the new extended half‐life factor concentrates (2017) (50)
Elastin Polymorphism Haplotype and Intracranial Aneurysms Are Not Associated in Central Europe (2003) (50)
Discrepancy between one-stage and chromogenic factor VIII activity assay results can lead to misdiagnosis of haemophilia A phenotype (2010) (50)
First prospective report on immune tolerance in poor risk haemophilia A inhibitor patients with a single factor VIII/von Willebrand factor concentrate in an observational immune tolerance induction study (2016) (49)
Effects of HCV co-infection on apoptosis of CD4+ T-cells in HIV-positive patients. (2009) (48)
Liver histopathology in patients with concurrent chronic hepatitis C and HIV infection (1997) (48)
Efficacy and safety of BAY 81‐8973, a full‐length recombinant factor VIII: results from the LEOPOLD I trial (2016) (48)
Prevalence of nucleic acid sequences specific for human parvoviruses, hepatitis A and hepatitis E viruses in coagulation factor concentrates (2011) (47)
11 Hemophilia A Patients without Mutations in the Factor VIII Encoding Gene (2002) (47)
Surgical Experience in Two Multicenter, Open-Label Phase 3 Studies of Emicizumab in Persons with Hemophilia A with Inhibitors (HAVEN 1 and HAVEN 2) (2017) (46)
Mutation Profiling in Haemophilia A (2001) (46)
Assay discrepancy in mild haemophilia A due to a factor VIII missense mutation (Asn694Ile) in a large Danish family (2000) (46)
Genetic markers in acquired haemophilia (2010) (46)
Association of a polymorphism of the ACVRL1 gene with sporadic arteriovenous malformations of the central nervous system. (2006) (45)
Core-specific adaptive regulatory T-cells in different outcomes of hepatitis C. (2010) (45)
F8 haplotype and inhibitor risk: results from the Hemophilia Inhibitor Genetics Study (HIGS) Combined Cohort (2013) (45)
Laboratory Monitoring in Emicizumab-Treated Persons with Hemophilia A (2019) (45)
NovoSeven® in immune tolerance therapy (2000) (44)
Frequency of contamination of coagulation factor concentrates with novel human parvovirus PARV4 (2008) (43)
Mutation distribution in the von Willebrand factor gene related to the different von Willebrand disease (VWD) types in a cohort of VWD patients (2012) (43)
Identification of eight novel coagulation factor XIII subunit A mutations: implied consequences for structure and function (2010) (43)
Factor VIII gene mutations found by a comparative study of SSCP, DGGE and CMC and their analysis on a molecular model of factor VIII protein (1997) (42)
A genome-wide association study of resistance to HIV infection in highly exposed uninfected individuals with hemophilia A. (2013) (42)
Long-acting recombinant factor VIII Fc fusion protein (rFVIIIFc) for perioperative haemostatic management in severe haemophilia A (2016) (42)
High factor VIII levels in venous thromboembolism show linkage to imprinted loci on chromosomes 5 and 11. (2005) (42)
Human VKORC1 mutations cause variable degrees of 4-hydroxycoumarin resistance and affect putative warfarin binding interfaces. (2013) (42)
The relevance of the bleeding severity in the treatment of acquired haemophilia – an update of a single‐centre experience with 67 patients (2008) (42)
SOCS1 and SOCS3 Target IRF7 Degradation To Suppress TLR7-Mediated Type I IFN Production of Human Plasmacytoid Dendritic Cells (2018) (41)
The definition, diagnosis and management of mild hemophilia A: communication from the SSC of the ISTH (2018) (41)
Hepatitis A Virus Infection among the Hemophilia Population at the Bonn Hemophilia Center (1994) (40)
Evidence for mast cell activation in patients with therapy-resistant irritable bowel syndrome. (2011) (39)
Development of inhibitory antibodies to therapeutic factor VIII in severe hemophilia A is associated with microsatellite polymorphisms in the HMOX1 promoter (2013) (39)
Label-Free Kinetic Studies of Hemostasis-Related Biomarkers Including D-Dimer Using Autologous Serum Transfusion (2015) (39)
Efficacy, safety and tolerability of recombinant factor VIII (REFACTO®) in patients with haemophilia A: interim data from a postmarketing surveillance study in Germany and Austria (2007) (39)
Warfarin and vitamin K compete for binding to Phe55 in human VKOR (2016) (39)
Serological and Virological Markers of Human Parvovirus B19 Infection in Sera of Hemophiliacs (1994) (38)
Methylation levels at selected CpG sites in the factor VIII and FGFR3 genes, in mature female and male germ cells: implications for male-driven evolution. (1998) (38)
Determination of the warfarin inhibition constant Ki for vitamin K 2,3-epoxide reductase complex subunit-1 (VKORC1) using an in vitro DTT-driven assay. (2013) (37)
Characterization of duplication breakpoints in the factor VIII gene (2010) (37)
Emicizumab Prophylaxis Provides Flexible and Effective Bleed Control in Children with Hemophilia Α with Inhibitors: Results from the HAVEN 2 Study (2018) (37)
Structure functional insights into calcium binding during the activation of coagulation factor XIII A (2019) (37)
Monitoring of plasma levels of activated protein C using a clinically applicable oligonucleotide‐based enzyme capture assay (2012) (37)
Coagulation activation and fibrinolysis impairment are reduced in patients with anxiety and depression when medicated with serotonergic antidepressants (2011) (36)
A common 253‐kb deletion involving VWF and TMEM16B in German and Italian patients with severe von Willebrand disease type 3 (2007) (36)
Familial molar tissues due to mutations in the inflammatory gene, NALP7, have normal postzygotic DNA methylation (2006) (36)
A new cell culture‐based assay quantifies vitamin K 2,3‐epoxide reductase complex subunit 1 function and reveals warfarin resistance phenotypes not shown by the dithiothreitol‐driven VKOR assay (2013) (36)
Recombinant factor VIII Fc fusion protein for the treatment of severe haemophilia A: Final results from the ASPIRE extension study (2020) (36)
Factor VIII intron‐1 inversion: frequency and inhibitor prevalence (2006) (35)
Increased frequency of the CTLA‐4 49 A/G polymorphism in patients with acquired haemophilia A compared to healthy controls (2008) (35)
Postauthorization safety surveillance of ADVATE [antihaemophilic factor (recombinant), plasma/albumin‐free method] demonstrates efficacy, safety and low‐risk for immunogenicity in routine clinical practice (2010) (34)
Whole Blood DNA Aberrant Methylation in Pancreatic Adenocarcinoma Shows Association with the Course of the Disease: A Pilot Study (2012) (34)
Lithuanian haemophilia A and B registry comprising phenotypic and genotypic data (2001) (34)
Cancer risk in HIV-infected individuals on HAART is largely attributed to oncogenic infections and state of immunocompetence (2011) (34)
Inter-locus as well as intra-locus heterogeneity in LINE-1 promoter methylation in common human cancers suggests selective demethylation pressure at specific CpGs (2015) (34)
Gain‐of‐Function Mutation in STIM1 (P.R304W) Is Associated with Stormorken Syndrome (2014) (33)
Thrombin inhibition profiles in healthy individuals and thrombophilic patients (2012) (33)
Alloantibodies to therapeutic factor VIII in hemophilia A: the role of von Willebrand factor in regulating factor VIII immunogenicity (2015) (33)
Elevated Interleukin-6 Concentration and Alterations of the Coagulation System Are Associated with the Development of Intraventricular Hemorrhage in Extremely Preterm Infants (2012) (33)
Novel, human cell line‐derived recombinant factor VIII (human‐cl rhFVIII; Nuwiq®) in adults with severe haemophilia A: efficacy and safety (2016) (33)
Identification of 32 novel mutations in the factor VIII gene in Indian patients with hemophilia A. (2005) (33)
HLA genotype in patients with acquired haemophilia A (2010) (33)
Porphyromonas gingivalis Outer Membrane Vesicles Induce Selective Tumor Necrosis Factor Tolerance in a Toll-Like Receptor 4- and mTOR-Dependent Manner (2016) (32)
Improved joint health in subjects with severe haemophilia A treated prophylactically with recombinant factor VIII Fc fusion protein (2018) (32)
Revisiting the mechanism of coagulation factor XIII activation and regulation from a structure/functional perspective (2016) (32)
Mutations affecting disulphide bonds contribute to a fairly common prevalence of F13B gene defects: results of a genetic study in 14 families with factor XIII B deficiency (2010) (32)
The prevalence of antibody to parvovirus B19 in hemophiliacs and in the general population. (1996) (32)
Significance of F8 missense mutations with respect to inhibitor formation (2013) (31)
Long-term safety and efficacy of extended-interval prophylaxis with recombinant factor IX Fc fusion protein (rFIXFc) in subjects with haemophilia B (2016) (31)
Bleeding and non-bleeding phenotypes in patients with GGCX gene mutations. (2014) (31)
Monitoring the progression of the in vitro selection of nucleic acid aptamers by denaturing high-performance liquid chromatography (2008) (31)
Deletion of human GP1BB and SEPT5 is associated with Bernard-Soulier syndrome, platelet secretion defect, polymicrogyria, and developmental delay (2011) (31)
Methylation of L1Hs promoters is lower on the inactive X, has a tendency of being higher on autosomes in smaller genomes and shows inter-individual variability at some loci (2011) (31)
Lack of F8 mRNA: a novel mechanism leading to hemophilia A. (2006) (31)
Identification of deep intronic variants in 15 haemophilia A patients by next generation sequencing of the whole factor VIII gene (2015) (30)
Outcome after total knee arthroplasty in haemophilic patients with stiff knees (2015) (30)
Total ankle replacement in patients with haemophilia and virus infections – a safe alternative to ankle arthrodesis? (2014) (30)
Molecular biology of blood coagulation. (2001) (30)
Prophylaxis vs. on‐demand treatment with Nuwiq® (Human‐cl rhFVIII) in adults with severe haemophilia A (2016) (29)
Two enzymes catalyze vitamin K 2,3-epoxide reductase activity in mouse: VKORC1 is highly expressed in exocrine tissues while VKORC1L1 is highly expressed in brain. (2015) (29)
Functional promoter polymorphism in the VKORC1 gene is no major genetic determinant for coronary heart disease in Northern Germans (2007) (29)
Intron retention resulting from a silent mutation in the VWF gene that structurally influences the 5' splice site. (2016) (29)
Bleeding and safety outcomes in persons with haemophilia A without inhibitors: Results from a prospective non‐interventional study in a real‐world setting (2019) (29)
Bleeding diathesis in patients with mast cell activation disease (2011) (29)
The coagulation system of extremely preterm infants: influence of perinatal risk factors on coagulation (2012) (28)
Phenotype – genotype correlation in eight Polish patients with inherited Factor XIII deficiency: identification of three novel mutations (2007) (27)
Recombinant expression of mutations causing von Willebrand disease type Normandy: characterization of a combined defect of factor VIII binding and multimerization (2004) (27)
In silico calculated affinity of FVIII‐derived peptides for HLA class II alleles predicts inhibitor development in haemophilia A patients with missense mutations in the F8 gene (2014) (27)
Increased circulating levels of neurotrophins and elevated expression of their high-affinity receptors on skin and gut mast cells in mastocytosis. (2013) (27)
Pattern of bleeding in a large prospective cohort of haemophilia A patients: A three‐year follow‐up of the AHEAD (Advate in HaEmophilia A outcome Database) study (2018) (26)
Determination of Plasma Heparin Level Improves Identification of Systemic Mast Cell Activation Disease (2015) (26)
ITI choice for the optimal management of inhibitor patients – from a clinical and pharmacoeconomic perspective (2014) (26)
Long‐term outcome of total hip arthroplasty in patients with haemophilia (2017) (26)
Impact of pharmacokinetic (CYP2C9) and pharmacodynamic (VKORC1, F7, GGCX, CALU, EPHX1) gene variants on the initiation and maintenance phases of phenprocoumon therapy (2010) (26)
Perioperative management and outcome of general and abdominal surgery in hemophiliacs. (2010) (26)
Variable resistance to freezing and thawing of CD34-positive stem cells and lymphocyte subpopulations in leukapheresis products. (2016) (26)
Antiviral therapy for hepatitis C virus recurrence after liver transplantation in HIV-infected patients: outcome in the Bonn cohort (2007) (26)
Health‐related quality of life and health status in persons with haemophilia A with inhibitors: A prospective, multicentre, non‐interventional study (NIS) (2019) (26)
The genetic diversification of the HIV type 1 gag p17 gene in patients infected from a common source. (1995) (26)
Detection of heterozygous large deletions in the antithrombin gene using multiplex polymerase chain reaction and denatured high performance liquid chromatography. (2006) (26)
The history of FEIBA: a lifetime of success in the treatment of haemophilia complicated by an inhibitor (2006) (26)
Patients with familial biparental hydatidiform moles have normal methylation at imprinted genes (2005) (25)
NOTCH4 gene polymorphisms as potential risk factors for brain arteriovenous malformation development and hemorrhagic presentation. (2017) (25)
Comparative genetics of warfarin resistance (2013) (25)
Factor 5 mutation profile in German patients with homozygous and heterozygous factor V deficiency (2009) (25)
Characterisation of patients with Glanzmann thrombasthenia and identification of 17 novel mutations (2014) (25)
Faktor-XIII-Mangelerkrankungen (2014) (25)
Identification of VKORC1 interaction partners by split-ubiquitin system and coimmunoprecipitation (2010) (25)
VKORC1 and VKORC1L1: Why do Vertebrates Have Two Vitamin K 2,3-Epoxide Reductases? (2015) (25)
Misalignment of lung vessels and alveolar capillary dysplasia (1995) (24)
Retrochorionic hematoma in congenital afibrinogenemia: Resolution with fibrinogen concentrate infusions (2007) (24)
Immunosuppressive treatment for acquired haemophilia: current practice and future directions in Germany, Austria and Switzerland (2009) (23)
Mutations in haemophilia A (1993) (23)
Prediction of phenprocoumon maintenance dose and phenprocoumon plasma concentration by genetic and non-genetic parameters (2010) (23)
An evaluation Zequanox ® efficacy and application strategies for targeted control of zebra mussels in shallow-water habitats in lakes (2015) (22)
Historical Review on Genetic Analysis in Hemophilia A (2014) (22)
Extracorporeal Treatment for the Acute und Long-Term Outcome of Patients with Life-Threatening Acquired Hemophilia (2012) (22)
Large deletions identified in patients with von Willebrand disease using multiple ligation‐dependent probe amplification (2011) (22)
Coagulation Factor IX Propeptide Mutations Causing Coumarin Hypersensitivity: Identification of Female Alanine-10 Valine Heterozygotes (2001) (22)
Genetic Predisposition to Bleeding during Oral Anticoagulant Therapy: Evidence for Common Founder Mutations (FIXVal-10 and FIXThr-10) and an Independent CpG Hotspot Mutation (FIXThr-10) (2001) (22)
Different inactivating mutations in the LU genes of three individuals with the Lutheran‐null phenotype (2007) (22)
TAVI induces an elevation of hemostasis-related biomarkers, which is not causative for post-TAVI thrombocytopenia. (2016) (22)
Co-activation through TLR4 and TLR9 but not TLR2 skews Treg-mediated modulation of Igs and induces IL-17 secretion in Treg:B cell co-cultures (2014) (22)
Acute Hepatitis C in Haemophiliacs Due to “Virus-Inactivated” Clotting Factor Concentrates (1992) (21)
Low‐titre inhibitors, undetectable by the Nijmegen assay, reduce factor VIII half‐life after immune tolerance induction (2012) (21)
Direct and indirect estimation of the sex ratio of mutation frequencies in hemophilia A. (1993) (21)
An Alu repeat-mediated genomic GCNT2 deletion underlies congenital cataracts and adult i blood group (2012) (20)
In vitro characterization of recombinant factor VIII concentrates reveals significant differences in protein content, activity and thrombin activation profile (2013) (20)
Pharmacokinetics of a novel extended half‐life glycoPEGylated factor IX, nonacog beta pegol (N9‐GP) in previously treated patients with haemophilia B: results from two phase 3 clinical trials (2017) (20)
Optimizing the management of patients with haemophilia A and inhibitors in the era of emicizumab: Recommendations from a German expert panel (2020) (20)
Detailed methylation map of LINE‐1 5′‐promoter region reveals hypomethylated CpG hotspots associated with tumor tissue specificity (2019) (20)
Identification and functional characterization of a novel F5 mutation (Ala512Val, FVBonn) associated with activated protein C resistance (2016) (20)
Bleeding events and safety outcomes in persons with haemophilia A with inhibitors: A prospective, multi‐centre, non‐interventional study (2018) (19)
NLRP7 inter-domain interactions: the NACHT-associated domain is the physical mediator for oligomeric assembly. (2014) (19)
Identification of a third rearrangement at Xq28 that causes severe hemophilia A as a result of homologous recombination between inverted repeats (2012) (19)
Transcatheter aortic valve implantation leads to a restoration of von Willebrand factor (VWF) abnormalities in patients with severe aortic stenosis - Incidence and relevance of clinical and subclinical VWF dysfunction in patients undergoing transfemoral TAVI. (2017) (19)
Genetic testing in bleeding disorders (2014) (19)
Prophylaxis in bleeding disorders. (2011) (19)
Founder mutation Arg485Pro led to recurrent compound heterozygous GGCX genotypes in two German patients with VKCFD type 1 (2006) (19)
F8 genetic analysis strategies when standard approaches fail (2013) (19)
Successful angiographic embolization of recurrent elbow and knee joint bleeds in seven patients with severe haemophilia (2009) (18)
Congenital combined deficiency of coagulation factors VII and X – different genetic mechanisms (2015) (18)
The Arg98Trp mutation in human VKORC1 causing VKCFD2 disrupts a di-arginine-based ER retention motif. (2014) (18)
Erratum: Diagnosis and Management of Vaccine-Related Thrombosis following AstraZeneca COVID-19 Vaccination: Guidance Statement from the GTH (2021) (18)
Eight novel F13A1 gene missense mutations in patients with mild FXIII deficiency: in silico analysis suggests changes in FXIII-A subunit structure/function (2014) (18)
Recombinant FXIII (rFXIII-A 2 ) Prophylaxis Prevents Bleeding and Allows for Surgery in Patients with Congenital FXIII A-Subunit Deficiency (2018) (18)
The importance of inhibitor eradication in clinically complicated hemophilia A patients (2018) (18)
Emicizumab Prophylaxis in Adolescent/Adult Patients with Hemophilia A Previously Receiving Episodic or Prophylactic Bypassing Agent Treatment: Updated Analyses from the HAVEN 1 Study (2017) (18)
Analysis of F8 mRNA in haemophilia A patients with silent mutations or presumptive splice site mutations (2013) (17)
Treatment of the antiphospholipid syndrome with direct oral anticoagulantsPosition statement of German societies. (2019) (17)
Clinical manifestation of hemophilia A in the absence of mutations in the F8 gene that encodes FVIII: role of microRNAs (2019) (17)
Long‐term outcome of haemophilia A patients after successful immune tolerance induction therapy using a single plasma‐derived FVIII/VWF product: the long‐term ITI study (2016) (17)
Three different hepatocyte transplantation techniques for enzyme deficiency disease and acute hepatic failure. (1992) (17)
Vitamin K intake and stability of oral anticoagulant treatment (2005) (17)
Haemophilia Inhibitor Genetics Study – evaluation of a model for studies of complex diseases using linkage and association methods (2005) (17)
Patient data meta‐analysis of Post‐Authorization Safety Surveillance (PASS) studies of haemophilia A patients treated with rAHF‐PFM (2014) (17)
DNA methylation at selected CpG sites in peripheral blood leukocytes is predictive of gastric cancer. (2014) (17)
Malignant disease in the haemophilic population: moving towards a management consensus? (2012) (17)
Practical Guidance of the GTH Haemophilia Board on the Use of Emicizumab in Patients with Haemophilia A (2020) (17)
Unusual genomic rearrangements in introns 1 and 22 of the F8 gene (2011) (17)
Developing the First Recombinant Factor XIII for Congenital Factor XIII Deficiency: Clinical Challenges and Successes (2016) (16)
MALDI Imaging of predictive ferritin, fibrinogen and proteases in haemophilic arthropathy (2014) (16)
Genomics of bleeding disorders (2014) (16)
A Validated HPLC Method for the Determination of Vitamin K in Human Serum – First Application in a Pharmacological Study (2011) (16)
Long‐term safety and sustained efficacy for up to 5 years of treatment with recombinant factor IX Fc fusion protein in subjects with haemophilia B: Results from the B‐YOND extension study (2020) (16)
Analysis of expression kinetics and activity of a new B-domain truncated and full-length FVIII protein in three different cell lines (1999) (16)
Coagulation Factor XIIIA Subunit Missense Mutations Affect Structure and Function at the Various Steps of Factor XIII Action (2016) (16)
Urological surgery in patients with hemorrhagic bleeding disorders Hemophilia A, Hemophilia B, von Willebrand disease: a retrospective study with matched pairs analysis (2013) (16)
Potential biomarkers of haemophilic arthropathy: correlations with compatible additive magnetic resonance imaging scores (2016) (15)
β-Propiolactone UV Inactivated Clotting Factor Concentrate Is the Source of HIV-Infection of 8 Hemophilia B Patients: Confirmed (1995) (15)
Bleeding symptoms in patients diagnosed as type 3 von Willebrand disease: Results from 3WINTERS‐IPS, an international and collaborative cross‐sectional study (2020) (15)
Genetic variants of the vitamin K dependent coagulation system and intraventricular hemorrhage in preterm infants (2014) (15)
Measurements of DNA Methylation at Seven Loci in Various Tissues of CD1 Mice (2012) (15)
Progression of liver fibrosis in HIV/HCV genotype 1 co-infected patients is related to the T allele of the rsI2979860 polymorphism of the IL28B gene (2011) (15)
Safety and efficacy of BAY 81‐8973 for surgery in previously treated patients with haemophilia A: results of the LEOPOLD clinical trial programme (2016) (15)
Tamoxifen induces resistance to activated protein C. (2014) (15)
The B-cell epitope of the monoclonal anti-factor VIII antibody ESH8 characterized by peptide array analysis (2008) (15)
Parallel evolution in the V3 region of HIV type 1 after infection of hemophiliacs from a homogeneous source. (1994) (15)
Insights into pathological mechanisms of missense mutations in C-terminal domains of von Willebrand factor causing qualitative or quantitative von Willebrand disease (2013) (15)
55th Annual Meeting of the GTH (2011) (15)
Identical point mutations in the factor VIII gene that have different clinical manifestations of hemophilia A. (1990) (15)
Immune tolerance induction: a role for recombinant activated factor VII (rFVIIa)? (1998) (14)
Long‐term safety and efficacy of turoctocog alfa in prophylaxis and treatment of bleeding episodes in severe haemophilia A: Final results from the guardian 2 extension trial (2018) (14)
Upper ankle joint prostheses in haemophilia patients (2009) (14)
Health-related quality-of-life and treatment satisfaction of individuals with hemophilia A treated with turoctocog alfa pegol (N8-GP): a new recombinant extended half-life FVIII (2019) (14)
Structural Modeling Insights into Human VKORC1 Phenotypes (2015) (14)
NLRP7, Involved in Hydatidiform Molar Pregnancy (HYDM1), Interacts with the Transcriptional Repressor ZBTB16 (2015) (14)
Kinetic parameters of monoclonal antibodies ESH2, ESH4, ESH5, and ESH8 on coagulation factor VIII and their influence on factor VIII activity (2009) (14)
Immunoadsorption in the treatment of acquired haemophilia. (2009) (14)
Comparison of F13A1 gene mutations in 73 patients treated with recombinant FXIII‐A2 (2017) (14)
Regulation of human factor IX expression using doxycycline-inducible gene expression system (2003) (13)
Rehabilitation of synovitis in patients with haemophilia (2007) (13)
VKORC1 and VKORC1L1 have distinctly different oral anticoagulant dose-response characteristics and binding sites. (2018) (13)
Identification of novel mutations in congenital afibrinogenemia patients and molecular modeling of missense mutations in Pakistani population (2017) (13)
Association of COMT genotypes with S-COMT promoter methylation in growth-discordant monozygotic twins and healthy adults (2011) (13)
Efficacy and safety of simoctocog alfa (Nuwiq®) in patients with severe hemophilia A: a review of clinical trial data from the GENA program (2019) (13)
Impact of interleukin 6 promoter polymorphisms (−174 G > C, −572 G > C and −597 G > A) on plasma IL-6 levels and their influence on the development of DVT: a study from India (2018) (13)
Summary report of the First International Conference on inhibitors in haemophilia A. (2017) (13)
Male-to-female transmission of HIV in a cohort of hemophiliacs — Frequency, risk factors and effect of sexual counseling (2005) (13)
γAla82Gly represents a common fibrinogen γ-chain variant in Caucasians (2005) (13)
Detection and characterisation of two missense mutations at a cleavage site in the factor VIII light chain. (1991) (13)
Assessing bleeding rates, related clinical impact and factor utilization in German hemophilia B patients treated with extended half-life rIX-FP compared to prior drug therapy (2020) (13)
Efficient factor VIII affinity purification using a small synthetic ligand (2008) (13)
Pattern and Evolution of BCR-ABL Kinase Domain Mutations in Patients with Philadelphia-Positive Acute Lymphoblastic Leukemia (Ph+ALL) Developing Resistance to Imatinib. (2005) (12)
VKORC1-dependent pharmacokinetics of intravenous and oral phylloquinone (vitamin K1) mixed micelles formulation (2012) (12)
Antibodies to factor VIII in hemophilia A patients. (2000) (12)
Impact of Telemedicine Tools on Record Keeping and Compliance in Haemophilia Care (2019) (12)
Haemophilia A diagnosis by automated fluorescent DNA detection of ten factor VIII intron 13 dinucleotide repeat alleles. (1994) (12)
Experiences with recombinant factor VIII products: development of inhibitors and immune tolerance therapy. (1998) (12)
F8 Inversions at Xq28 Causing Hemophilia A Are Associated With Specific Methylation Changes: Implication for Molecular Epigenetic Diagnosis (2019) (12)
Risk Factors for the Progression from Low to High Titres in 260 Children with Severe Haemophilia A and Newly Developed Inhibitors (2017) (12)
Investigating potential mechanisms underlying FVIII inhibition in acquired hemophilia A associated with mRNA COVID‐19 vaccines (2022) (12)
Phylogeny of the Vitamin K 2,3-Epoxide Reductase (VKOR) Family and Evolutionary Relationship to the Disulfide Bond Formation Protein B (DsbB) Family (2015) (12)
Risk stratification integrating genetic data for factor VIII inhibitor development in patients with severe hemophilia A (2019) (12)
Congenital hypersensitivity to vitamin K antagonists due to FIX propeptide mutation at locus -10: a (not so) rare cause of bleeding under oral anticoagulant therapy in Switzerland. (2008) (12)
gammaAla82Gly represents a common fibrinogen gamma-chain variant in Caucasians. (2005) (12)
Prophylaxis and quality of life in patients with hemophilia A during routine treatment with ADVATE [antihemophilic factor (recombinant), plasma/albumin-free method] in Germany: a subgroup analysis of the ADVATE PASS post-approval, non-interventional study (2013) (11)
Transcriptome-wide analysis of filarial extract-primed human monocytes reveal changes in LPS-induced PTX3 expression levels (2019) (11)
Activated Factor X-Based versus Thrombin-Based Antithrombin Testing in Thrombophilia Workup in the DOAC Era (2018) (11)
Genetic background and inhibitors in previously untreated or minimally treated young patients with severe haemophilia A treated with sucrose-formulated recombinant factor VIII (2006) (11)
Structural and functional influences of coagulation factor XIII subunit B heterozygous missense mutants (2015) (11)
Skewed X-chromosome inactivation and XIST locus methylation levels do not contribute to the lower prevalence of Parkinson's disease in females (2017) (11)
Spotlight on the human factor: building a foundation for the future of haemophilia A management (2015) (11)
Inhibitory oligodeoxynucleotides downregulate herpes simplex virus-induced plasmacytoid dendritic cell type I interferon production and modulate cell function. (2007) (10)
Global Seroprevalence of Pre-existing Immunity Against AAV5 and Other AAV Serotypes in People with Hemophilia A (2022) (10)
Health‐related quality of life and caregiver burden of emicizumab in children with haemophilia A and factor VIII inhibitors—Results from the HAVEN 2 study (2020) (10)
Use of Bypassing Agents Prior to and Post Bypassing Agent Dosing Guidance during Emicizumab Prophylaxis: Analyses from the HAVEN 1 Study (2017) (10)
The effect of emicizumab prophylaxis on long‐term, self‐reported physical health in persons with haemophilia A without factor VIII inhibitors in the HAVEN 3 and HAVEN 4 studies (2021) (10)
Impact of Hormone-Associated Resistance to Activated Protein C on the Thrombotic Potential of Oral Contraceptives: A Prospective Observational Study (2014) (10)
The Plasma Factor XIII Heterotetrameric Complex Structure: Unexpected Unequal Pairing within a Symmetric Complex (2019) (10)
Sequencing of the factor 8(F8) coding regions in 10 Turkish hemophilia A patients reveals three novel pathological mutations, and one rediagnosis of von Willebrand's disease type 2N (2006) (10)
Successful pain treatment in arthropathic lower extremities by acupuncture in haemophilia patients (2006) (10)
PROTECTING JUVENILE SALMONIDS FROM GULL PREDATION USING WIRE EXCLUSION BELOW HYDROELECTRIC DAMS (1995) (10)
Once‐weekly prophylaxis with 40 IU/kg nonacog beta pegol (N9‐GP) achieves trough levels of >15% in patients with haemophilia B: Pooled data from the paradigm™ trials (2018) (10)
Modelling and expression studies of two novel mutations causing factor V deficiency (2008) (9)
Genome-wide transcriptome induced by nickel in human monocytes. (2016) (9)
In Vitro Evaluation of Aptamer-Based Reversible Inhibition of Anticoagulant Activated Protein C as a Novel Supportive Hemostatic Approach. (2016) (9)
ENDANGERED SPECIES IN THE PACIFIC ISLANDS: THE ROLE OF ANIMAL DAMAGE CONTROL (1992) (9)
Interim results from a large multinational extension trial (guardian™2) using turoctocog alfa for prophylaxis and treatment of bleeding in patients with severe haemophilia A (2016) (9)
Radiosynoviorthesis in hemophilic arthropathy: pathologic blood pool imaging on pre-therapeutic bone scintigraphy is not a predictor of treatment success (2016) (9)
The first case of combined coagulation factor V and coagulation factor VIII deficiency in Poland due to a novel p.Tyr135Asn missense mutation in the MCFD2 gene (2008) (9)
Subclinical hyperthyroidism seems not to have a significant impact on systemic anticoagulation in patients with coumarin therapy (2008) (9)
Effect of F8 B domain gene variants on synthesis, secretion, activity and stability of factor VIII protein (2013) (9)
Activity Pattern Analysis Indicates Increased but Balanced Systemic Coagulation Activity in Response to Surgical Trauma (2018) (9)
Molecular characterization of five Italian families with inherited severe factor XIII deficiency (2007) (9)
High adherence to prophylaxis regimens in haemophilia B patients receiving rIX‐FP: Evidence from clinical trials and real‐world practice (2020) (9)
Evidence of pathogenicity of a mutation in 3′ untranslated region causing mild haemophilia A (2016) (9)
Disruption of Structural Disulfides of Coagulation FXIII-B Subunit; Functional Implications for a Rare Bleeding Disorder (2019) (9)
Type‐3 von Willebrand disease in India—Clinical spectrum and molecular profile (2018) (9)
Heterozygous large deletions of Factor 8 gene in females identified by multiplex PCR‐LC (2008) (9)
In Vitro Secretion Deficits are Common Among Human Coagulation Factor XIII Subunit B Missense Mutants: Correlations with Patient Phenotypes and Molecular Models (2013) (9)
Relative Hyperhomocysteinemia in Patients with Panic Disorder: A Case-Control Study (2010) (9)
[Muscular compartment syndrome of the forearm in a haemophilia inhibitor patient]. (2008) (8)
Outcomes in children with hemophilia A with inhibitors: Results from a noninterventional study (2020) (8)
Safety, efficacy and pharmacokinetics of nonacog beta pegol (N9-GP) for prophylaxis and treatment of bleeding episodes in patients with haemophilia B (2013) (8)
Polymorphisms in VKORC1 and GGCX are not major genetic determinants of vitamin K-dependent coagulation factor activity in Western Germans (2009) (8)
Molecular insights and functional consequences of the interaction of heme with activated protein C. (2020) (8)
Identification of Potential Novel Interacting Partners for Coagulation Factor XIII B (FXIII-B) Subunit, a Protein Associated with a Rare Bleeding Disorder (2019) (8)
Increased Activated Protein C Response Rates Reduce the Thrombotic Risk of Factor V Leiden Carriers but not of Prothrombin 20210G>A Carriers. (2019) (8)
Haemophilia A in a female caused by coincidence of a Swyer syndrome and a missense mutation in factor VIII gene (2006) (8)
Sequence of the rat factor VIII cDNA (2003) (8)
Quality management and quality assurance in haemophilia care: a model at the Bonn haemophilia centre (2002) (8)
Diversification of HIV-1 strains after infection from a unique source. (1993) (8)
[2% Haemophilia A patients without mutation in the FVIII gene]. (2003) (8)
Coagulation Factor XIIIa Inhibitor Tridegin: On the Role of Disulfide Bonds for Folding, Stability, and Function. (2019) (8)
Tris(3-hydroxypropyl)phosphine is superior to dithiothreitol for in vitro assessment of vitamin K 2,3-epoxide reductase activity. (2015) (7)
Simoctocog Alfa (Nuwiq) in Previously Untreated Patients with Severe Haemophilia A: Final Results of the NuProtect Study (2021) (7)
Inhibitors to Factor VIII—Molecular Basis (2007) (7)
In vivo thrombin generation and subsequent APC formation are increased in factor V Leiden carriers. (2018) (7)
Falling and fall risk in adult patients with severe haemophilia (2016) (7)
Value and risk of laparoscopic surgery in hemophiliacs—experiences from a tertiary referral center for hemorrhagic diatheses (2014) (7)
Understanding FVIII/VWF complex – report from a symposium of XXIX WFH meeting 2010 (2012) (7)
Fifteen years of Env C2V3C3 evolution in six individuals infected clonally with human immunodeficiency virus type 1 (2007) (7)
SARS-CoV-2 Infection: Modulator of Pulmonary Embolism Paradigm (2021) (7)
Molecular genetics in haemophilia A. (2000) (7)
Modified expression of coagulation factor VIII by addition of a glycosylation site at the N terminus of the protein (2008) (7)
A common F13A1 intron 1 variant IVS1+12(A) is associated with mild FXIII deficiency in Caucasian population (2013) (7)
Treatment of Factor VIII Inhibitors with Selective IgG Immunoadsorption – a Single Center Experience in 50 Patients with Acquired Hemophilia* (2006) (7)
Treatment of acute pulmonary haemorrhage in extremely preterm infants with recombinant activated factor VII (2009) (7)
First report of a FVII-deficient Indian patient carrying double heterozygous mutations in the FVII gene. (2005) (7)
Transient elastography discloses identical distribution of liver fibrosis in chronic hepatitis C between HIV-negative and HIV-positive patients on HAART. (2009) (7)
Effects of the CCR5-Δ32 Mutation on Hepatitis C Virus-Specific Immune Responses in Patients with Haemophilia (2009) (7)
Protamine-adsorbed magnetic nanoparticles for efficient isolation and concentration of hepatitis-C virus from human plasma samples. (2014) (7)
Deletion of human GP 1 BB and SEPT 5 is associated with Bernard-Soulier syndrome , platelet secretion defect , polymicrogyria , and develop-mental delay (2018) (7)
Short-term venous stasis induces fibrinolytic activation but not thrombin formation. (2014) (7)
Capture and Release (CaR): a simplified procedure for one-tube isolation and concentration of single-stranded DNA during SELEX. (2015) (7)
Quality of electronic treatment records and adherence to prophylaxis in haemophilia and von Willebrand disease: Systematic assessments from an electronic diary (2020) (7)
Correlation of transient elastography with APRI and FIB‐4 in a cohort of patients with congenital bleeding disorders and HCV or HIV/HCV coinfection (2010) (7)
Phase 1-2 Trial of AAVS3 Gene Therapy in Patients with Hemophilia B. (2022) (7)
Effects of the CCR5-Δ32 Mutation on Hepatitis C Virus-Specific Immune Responses in Patients with Haemophilia (2009) (7)
Characterization of a novel large deletion caused by double-stranded breaks in 6-bp microhomologous sequences of intron 11 and 12 of the F13A1 gene (2016) (7)
Emicizumab Prophylaxis in Persons with Mild or Moderate Hemophilia A: Results from the Interim Analysis of the HAVEN 6 Study (2021) (6)
Clinical overview of Fanhdi/Alphanate (plasma‐derived, VWF‐containing FVIII concentrate) in immune tolerance induction in haemophilia A patients with inhibitors (2016) (6)
Mutational spectrum and deep intronic variants in the factor VIII gene of haemophilia A patients (2016) (6)
The problem of novel FVIII missense mutations for haemophilia A genetic counseling (2009) (6)
NLRP 7 , Involved in Hydatidiform Molar Pregnancy ( HYDM 1 ) , Interacts with the Transcriptional Repressor ZBTB 16 (2015) (6)
Expression studies of mutant factor VIII alleles with premature termination codons with regard to inhibitor formation (2014) (6)
[Characterization of factor VIII antibody epitopes from haemophilia A patients using cellulose bound FVIII peptide libraries]. (2003) (6)
Turoctocog alfa (recombinant factor VIII) (2015) (6)
Variants in FIX propeptide associated with vitamin K antagonist hypersensitivity: functional analysis and additional data confirming the common founder mutations (2018) (6)
Selective Modulation of the Protease Activated Protein C Using Exosite Inhibiting Aptamers. (2020) (6)
Recurrent intracardiac thrombosis as an unusual manifestation of inherited thrombophilia. (2007) (6)
Reference materials (RMs) for analysis of the human factor II (prothrombin) gene G20210A mutation (2005) (6)
[Immune tolerance therapy for inhibitors in haemophilia A]. (2008) (6)
Molecular analysis of FVIII gene in severe HA patients of Costa Rica (2010) (6)
11p15 DNA-methylation analysis in monozygotic twins with discordant intrauterine development due to severe twin-to-twin transfusion syndrome (2014) (6)
Genetic Basis of Inhibitor Development in Severe Haemophilia A and B (2008) (6)
Real-World Rates of Bleeding, Factor VIII Use, and Quality of Life in Individuals with Severe Haemophilia A Receiving Prophylaxis in a Prospective, Noninterventional Study (2021) (6)
Health‐related quality of life and health status in adolescent and adult people with haemophilia A without factor VIII inhibitors—A non‐interventional study (2021) (6)
Estimation of Nuwiq® (simoctocog alfa) activity using one‐stage and chromogenic assays—Results from an international comparative field study (2019) (6)
Prophylaxis in adult patients with severe haemophilia A. (2014) (6)
Effects of Primary Mast Cell Disease on Hemostasis and Erythropoiesis (2021) (6)
Two years' experience with two recombinant factor VIII concentrates (1993) (5)
Surgical outcomes in people with hemophilia A taking emicizumab prophylaxis: experience from the HAVEN 1-4 studies (2022) (5)
Design of a prospective observational study on the effectiveness and real-world usage of recombinant factor VIII Fc (rFVIIIFc) compared with conventional products in haemophilia A: the A-SURE study (2019) (5)
Molecular Analysis of Fetal and Adult Primary Human Liver Sinusoidal Endothelial Cells: A Comparison to Other Endothelial Cells (2020) (5)
Rapid and sustained immune tolerance to inhibitors induced by a plasma‐derived, VWF‐containing FVIII concentrate (2019) (5)
Treatment of minor severe acquired haemophilia. Is there a rationale for immunoadsorption? (2015) (5)
Functional lupus anticoagulant testing in a large retrospective cohort of thrombosis patients with direct oral anticoagulants (2020) (5)
Prevalence of Obesity in Young Patients with Severe Haemophilia and Its Potential Impact on Factor VIII Consumption in Germany (2019) (5)
Elective total knee arthroplasty in haemophilic patients (2014) (5)
Consensus Recommendations for Intramuscular COVID-19 Vaccination in Patients with Hemophilia (2021) (5)
Severe bleeding in two patients due to increased sensitivity of factor IX activity to phenprocoumon therapy (1997) (5)
Hemophilia A Patients with Undetectable Mutations: Current Knowledge and Future Directions* (2006) (5)
von Willebrand factor propeptide missense variants affect anterograde transport to Golgi resulting in ER retention (2021) (5)
GGCX mutations show different responses to vitamin K thereby determining the severity of the hemorrhagic phenotype in VKCFD1 patients (2021) (5)
[Impact of Preoperative Knee Stiffness on the Postoperative Outcome after Total Knee Arthroplasty in Patients with Haemophilia]. (2015) (5)
Mutations in severe hemophilia A: distribution within the factor VIII gene, origin and influence on inhibitor development. (1997) (5)
Development of an inhibitor-specific questionnaire for the assessment of health-related quality of life in haemophilia patients with inhibitors (INHIB-QoL) (2013) (5)
[The national GTH haemophilia registry as database within the scope of the German human genome project]. (2003) (5)
Bleeding Events and Safety Outcomes in Pediatric Persons with Hemophilia A with Inhibitors: The First Non-Interventional Study (NIS) from a Real-World Setting (2017) (5)
Characterization of the mutation spectrum in a Pakistani cohort of type 3 von Willebrand disease (2019) (5)
Haemophilia and knee function (2009) (5)
Role of factor VIII-binding capacity of endogenous von Willebrand factor in the development of factor VIII inhibitors in patients with severe hemophilia A (2019) (5)
Acquired deficiency of coagulation factor XIII—possible evidence for a new link between coagulation and infection from a case (2013) (5)
[Hemophiliac arthropathy of the knee joint. Gd-DTPA-enhanced MRI; clinical and roentgenological correlation]. (1994) (5)
▼Zoely: a new combined oral contraceptive (2014) (5)
Influence of treatment with haemostatic agents on ETP in patients with haemophilia and VWD (2008) (5)
[New insight in therapeutic anticoagulation by Coumarin derivatives]. (2008) (5)
Transient elastography discloses identical distribution of liver fibrosis in chronic hepatitis C between HIV-negative and HIV-positive patients on HAART (2010) (5)
Treatment‐related risk factors for inhibitor development in non‐severe hemophilia A after 50 cumulative exposure days: A case‐control study (2021) (5)
Characterisation of two novel large F8 deletions in patients with severe haemophilia A and factor VIII inhibitors (2010) (5)
Extended Half-Life Factor VIII/Factor IX Products: Assay Discrepancies and Implications for Hemophilia Management (2020) (5)
Identification of a novel factor X deletion in combination with a missense mutation in the F10 gene (2009) (5)
ASPIRE Final Results Confirm Established Safety and Sustained Efficacy for Up to 4 Years of Treatment With rFVIIIFc in Previously Treated Subjects With Severe Hemophilia A (2018) (5)
Distinct Expression and Function of FcεRII in Human B Cells and Monocytes (2017) (5)
Natural history study of factor IX deficiency with focus on treatment and complications (B‐Natural) (2020) (5)
Exploring the structural similarity yet functional distinction between coagulation factor XIII-B and complement factor H sushi domains (2019) (5)
Polymorphisms in the Promoter Region of the IL-10 Gene Is Associated with Inhibitor Development in Hemophilia A. (2005) (4)
Preference for Emicizumab over Prior Factor Treatments: Results from the HAVEN 3 and HAVEN 4 Studies (2018) (4)
New images in haemophilia (2008) (4)
Response to DDAVP in mild/moderate haemophilia A patients according to the underlying Factor VIII genotype (2003) (4)
NKG2D Engagement Alone Is Sufficient to Activate Cytokine-Induced Killer Cells While 2B4 Only Provides Limited Coactivation (2021) (4)
Genetic Factors Associated with Inhibitor Development in Hemophilia A: Initial Results From the Hemophilia Inhibitor Genetics Study (HIGS) Combined Cohort (2009) (4)
AHEAD. Advate in HaEmophilia A outcome Database. (2010) (4)
Combined coagulation factor VIII and factor IX deficiency (CDF8F9) in a patient from Lithuania (2016) (4)
In silico and in vitro evaluation of the impact of mutations in non-severe haemophilia A patients on assay discrepancies (2019) (4)
Correction to: Identification of novel mutations in congenital afibrinogenemia patients and molecular modeling of missense mutations in Pakistani population (2017) (4)
Novel characterization of a breakpoint in F8: an individualized approach to gene analysis when PCR and MLPA results contradict (2015) (4)
Functional and Structural Characterization of Nucleic Acid Ligands That Bind to Activated Coagulation Factor XIII (2021) (4)
Mild haemophilia A in a female patient with a large X‐chromosomal deletion and a missense mutation in the F8 gene – a case report (2013) (4)
Immune tolerance against infused FVIII in hemophilia A is mediated by PD-L1+ Tregs (2022) (4)
Giant haemophilic pseudotumour of the pelvis: case report and literature review (2015) (4)
[Comprehensive Care Center Bonn from 1980 to 2009. Changes in the epidemiology and regional composition of the haemophilia population]. (2011) (4)
[Flexion contracture in haemophilic knee arthropathy--10-year follow-up after hamstring release and dorsal capsulotomy]. (2007) (4)
[Significance of mutation analysis in patients with haemophilia A]. (2003) (4)
Immunoadsorption for Pregnancy‐Associated Severe Acquired Hemophilia (2014) (4)
Further Evidence That MicroRNAs Can Play a Role in Hemophilia A Disease Manifestation: F8 Gene Downregulation by miR-19b-3p and miR-186-5p (2020) (4)
Bleeding Events and Safety Outcomes in Patients with Hemophilia a with Inhibitors: A Prospective, Multicenter, Non-Interventional Study (2016) (3)
Selection of high affinity DNA-aptamer for activated protein C using capillary electrophoresis (2012) (3)
Changes of static and dynamic spine alignment in patients with severe haemophilia (2021) (3)
Methylation analysis of the promoter region and intron 1 of the factor VIII gene in haemophilia A patients (2013) (3)
Vitamin K Epoxide Reductase Complex Subunit 1-Like 1 (VKORC1L1) Inhibition Induces a Proliferative and Pro-inflammatory Vascular Smooth Muscle Cell Phenotype (2021) (3)
Emicizumab in people with moderate or mild haemophilia A (HAVEN 6): a multicentre, open-label, single-arm, phase 3 study. (2023) (3)
No increased bleeding risk for oral surgery in patients with severe congenital bleeding disorders due to intense perioperative management (2015) (3)
Haemophilia A: Carrier detection by DNA analysis (1988) (3)
Most subjectively affected joints in patients with haemophilia – what has changed after 20 years in Germany? (2022) (3)
Genetic Variability of the Factor VIII Gene in the Normal Population (2005) (3)
The European Association for Haemophilia and Allied Disorders Coagulation Factor Variant Databases (2015) (3)
Familial Multiple Coagulation Factor Deficiencies (FMCFDs) in a Large Cohort of Patients—A Single-Center Experience in Genetic Diagnosis (2021) (3)
IDELVION: A Comprehensive Review of Clinical Trial and Real-World Data (2022) (3)
Treatment options for haemophilic arthropathy of the elbow after failed conservative therapy (2014) (3)
[An uncommon cause of severe soft tissue bleeding during phenprocoumon treatment]. (2001) (3)
[Blood coagulation and hemorrhagic diathesis]. (2006) (3)
Haemophiliac pseudotumour: two case reports of patients with moderate haemophilia A. (2009) (3)
[Backpain and haemophilia]. (2008) (3)
Clinical and patient reported outcome of total ankle replacement compared to ankle fusion in end-stage heamophilic arthropathy (2020) (3)
Molecular Profiling of Liver Sinusoidal Endothelial Cells in Comparison to Hepatocytes: Reflection on Which Cell Type Should Be the Target for Gene Therapy (2020) (3)
Perioperative management and outcome of fracture treatment in patients with haemophilia without inhibitors (2016) (3)
Product type and the risk of inhibitor development in nonsevere haemophilia A patients: a case‒control study (2020) (3)
Chromogenic analysis of FIX activity in haemophilia B patients treated with nonacog beta pegol (2017) (3)
Long-term outcome of liver transplantation in HCV/HIV coinfected haemophilia patients (2014) (3)
B-YOND Final Results Confirm Established Safety, Sustained Efficacy, and Extended Dosing Interval for Up to 4 Years of Treatment With rFIXFc in Previously Treated Subjects With Severe Hemophilia B (2018) (3)
CD33 Delineates Two Functionally Distinct NK Cell Populations Divergent in Cytokine Production and Antibody-Mediated Cellular Cytotoxicity (2022) (3)
The Current Understanding of Molecular Pathogenesis of Quantitative von Willebrand Disease, Types 1 and 3 (2020) (3)
Long-term efficacy and safety of subcutaneous concizumab prophylaxis in hemophilia A and hemophilia A/B with inhibitors (2022) (3)
An Alu repeat-mediated genomic GCNT2 deletion underlies congenital cataracts and adult i blood group (2011) (3)
Prosthetic heart valves and rare hypersensitivity to vitamin K antagonists resulting from factor IX mutation: how to manage anticoagulation? (2010) (3)
F8 gene: embedded in a region of genomic instability representing a hotspot of complex rearrangements (2015) (3)
Treatment of Adults with Clinically Suspected Severe Thrombotic Thrombocytopenic Purpura – Experiences of a Single Centre (2007) (3)
Splice Site Mutations Effect on the F8 mRNA Splicing (2007) (3)
Electronic diaries in the management of haemophilia gene therapy: Perspective of an expert group from the German, Austrian and Swiss Society on Thrombosis and Haemostasis (GTH) (2022) (3)
Origins, Development, Current Challenges and Future Directions with Activated Prothrombin Complex Concentrate for the Treatment of Patients with Congenital Haemophilia with Inhibitors (2020) (3)
Novel point mutation in fibrinogen (Innsbruck; BβArg44Gly) (2015) (2)
Relevance of a single dose of 270 μg/kg recombinant factor VIIa for the treatment of patients with haemophilia and inhibitors (2009) (2)
Molecular Genetic Analysis of a Patient with Moderate Hemophilia A and Psychomotor Developmental Delay (2013) (2)
Two-Year Outcomes of Valoctocogene Roxaparvovec Therapy for Hemophilia A. (2023) (2)
Novel findings in two patients with late‐diagnosed afibrinogenaemia: intraosseous haemorrhage and fingertip necrosis (2009) (2)
Two de novo factor VIII gene mutations in the family of an isolated severe haemophilia A patient (2012) (2)
Safety and Efficacy of Emicizumab in Persons with Hemophilia a with or without FVIII Inhibitors: Pooled Data from Four Phase III Studies (HAVEN 1-4) (2020) (2)
VKCFD2 – from clinical phenotype to molecular mechanism (2016) (2)
Long-term safety and efficacy of extended-interval prophylaxis with recombinant factor IX Fc fusion protein ( rFIXFc ) in subjects with haemophilia (2017) (2)
Functional Characterization of Antithrombin Mutations by Monitoring of Thrombin Inhibition Kinetics (2021) (2)
Recurrent VTE in a heterozygote of the fibrinogen Aα IVS4+1G>T and Aα p.Arg168Ter mutation (2016) (2)
[Hemophilia A: molecular biology and carrier diagnosis]. (1994) (2)
Immune Tolerance Induction for FIX Inhibitors Using Combined B and T Cell Immune Modulation Therapy in Severe Hemophilia B (2018) (2)
The EAHAD coagulation factor variant databases (2014) (2)
Challenges and key lessons from the design and implementation of an international haemophilia registry supported by a pharmaceutical company (2020) (2)
Factor VIII gene (F8) mutation and inhibitor development in non-severe hemophilia A (2013) (2)
Recombinant Porcine Factor VIII Corrects Thrombin Generation and Improves Clot Structure In Vitro in Plasma Containing Anti-Factor VIII Inhibitory Antibodies (2011) (2)
Hemophilia treatment. Side effects during immune tolerance induction. (2000) (2)
Pharmacokinetics of Azidothymidine and its Major Metabolite Glucuronylazidothymidine in Hemophiliacs Coinfected With Human Immunodeficiency Virus and Chronic Hepatitis C (1998) (2)
[Congenital coagulopathies and coagulation factor inhibitors]. (2008) (2)
Functional Analysis of the Factor VIII B Domain (2005) (2)
Corrigendum to “Determination of the warfarin inhibition constant Ki for vitamin K 2,3-epoxide reductase complex subunit-1 (VKORC1) using an in vitro DTT-driven assay” [BBAGEN (2013) 4202–4210] (2014) (2)
Sevenfold risk for inhibitors in mild/moderate hemophilia A with factor VIII missense mutations in two distinct regions (2011) (2)
Efanesoctocog Alfa Prophylaxis for Patients with Severe Hemophilia A. (2023) (2)
[Current and future prospects in haemostasis]. (2006) (2)
A novel missense mutation in the FGB gene (p.Gly302Arg) leading to afibrinogenemia (2016) (2)
Massive muscle haematoma three months after starting vitamin K antagonist therapy for deep-vein thrombosis in an antithrombin deficient patient: Another case of factor IX propeptide mutation (2011) (2)
Detectable SARS-CoV-2 RNAemia in Critically Ill Patients, but Not in Mild and Asymptomatic Infections (2021) (2)
First Case of Laparoscopic Mini-Gastric Bypass for the Treatment of Morbid Obesity in Severe Haemophilia A (2018) (2)
Safety and Efficacy of Nonacog Beta Pegol (N9-GP) for Prophylaxis and Treatment of Bleeding Episodes in Previously-Treated Patients with Hemophilia B: Results from an Extension Trial (2014) (2)
Comprehensive Profiling of Blood Coagulation and Fibrinolysis Marker Reveals Elevated Plasmin-Antiplasmin Complexes in Parkinson’s Disease (2021) (2)
Identification of 18 High Risk F8 Mutations for Inhibitor Development in 2,700 Non-Severe Hemophilia A Patients (2013) (2)
The role of variant alleles of the mannose-binding lectin in the inhibitor development in severe hemophilia A. (2019) (2)
Multifaceted pathomolecular mechanism of a VWF large deletion involved in the pathogenesis of severe VWD (2021) (2)
Development of Inhibitory Antibodies to Therapeutic Factor VIII in Severe Hemophilia A Is Associated with Microsatellite Polymorphism in the HMOX1 promoter (2012) (2)
A Novel Mutation (Asp36Tyr) in the Vitamin K Epoxide Reductase Complex Subunit 1 Gene (VKORC1) Causes Increased Phenprocoumon Requirement (2006) (2)
Compound heterozygosity of the protein S-gene as a cause of severe cerebral sinovenous thrombosis in a 7-year-old child. (2010) (2)
Activated Factor XI is Increased in Plasma in Response to Surgical Trauma but not to Recombinant Activated FVII-Induced Thrombin Formation (2020) (2)
Untreated bleeds in people with hemophilia A in a noninterventional study and intrapatient comparison after initiating emicizumab in HAVEN 1–3 (2022) (2)
Aptamer loaded superparamagnetic beads for selective capturing and gentle release of activated protein C (2022) (2)
Long-Term Follow-up of Hemophilia a Patients Who Previously Showed Complete or Partial Success in Immune Tolerance Induction Therapy with a Single Plasma-Derived FVIII/VWF Product: Long-Term ITI Study (2015) (2)
Exploring Diverse Coagulation Factor XIII Subunit Expression Datasets: A Bioinformatic Analysis (2022) (1)
Infiltration and clustering of MHC-II+ antigen-presenting cells in the skin of patients with atopic dermatitis. (2020) (1)
Target plasma factor levels for personalized treatment in hämophilia: a Delphi consensus statement (2017) (1)
Clinical risk factors in the development of inhibitors in non-severe hemophilia A patients: the first results of the INSIGHT case-control study (2013) (1)
Quantitative analysis of mRNA-expression of genes involved in the vitamin K-cycle in mouse-tissue (2009) (1)
JAK1/2 inhibitor but not IL‐4 receptor alpha antibody suppresses allergen‐mediated activation of human basophils in vitro (2022) (1)
Bleeding Tendency of Carriers of Hemophilia A - Dependent on the Age of the Carriers? (2005) (1)
Real-world experience on the use of rIX-FP in patients with hemophilia B: interim results from a prospective, non-interventional study in Germany (2023) (1)
Efficacy and Safety of Subcutaneous Prophylaxis with Concizumab in Patients with Severe Hemophilia a without Inhibitors: Results from the Phase 2 explorer5 Trial (2019) (1)
Site-Directed Mutagenesis of VKORC1, the Target Protein of Coumarin-Type Anticoagulants (2006) (1)
VKORC1: the little big protein (2005) (1)
Efficacy and safety of valoctocogene roxaparvovec gene transfer for severe hemophilia A: results from the GENEr8-1 three-year analysis (2023) (1)
Modified secretion of coagulation factor VIII by addition of a glycosylation site at the N terminus (2008) (1)
Homozygosity Mapping of a Second Gene Locus for Hereditary Combined Deficiency of Vitamin K-Dependent Clotting Factors (FMFD) to Chromosome 16 (2004) (1)
Clinical Outcomes in Adults/Adolescents with Hemophilia B Treated Long Term with Recombinant Factor IX Fc Fusion Protein (rFIXFc) Prophylaxis: Interim Results of the B-Yond Extension Study (2016) (1)
Genotype-Phenotype Correlation in Hemophilia A (2001) (1)
Acute Hepatitis E Virus infection in a hemophilic patient with acquired inhibitor during immune tolerance therapy according to modified Bonn‐Malmö protocol (2019) (1)
FXIII Protein Inhibitor against the FXIII-A Subunit in an 8-Year-Old Boy with Inherited Severe Factor XIII Deficiency Complicated by Multiple Intracerebral Cavernomas (2020) (1)
Pharmacokinetic-Guided Prophylaxis with Rurioctocog Alfa Pegol Improves Bleeding Rates over Standard Prophylaxis: Real-World Observational Data from the Ahead German Study (2021) (1)
Quality of life in a large multinational haemophilia B cohort (The B‐Natural study) – Unmet needs remain (2022) (1)
Post hoc longitudinal assessment of efficacy and safety of recombinant factor IX Fc fusion protein in hemophilia B. (2023) (1)
Clinical management and outcome after laparoscopic surgery in hemophiliacs – a matched pairs analysis (2014) (1)
Membrane Properties of Human Induced Pluripotent Stem Cell-Derived Cultured Red Blood Cells (2022) (1)
Real World Prospective Data on Bleeding Frequency in 1,000 Patients with Hemophilia a - is the Goal of Zero Bleeds Achievable? (2017) (1)
Report of the Fifth Meeting of the International Network for Pediatric Hemophilia: a focus on prophylaxis and immune tolerance induction (2011) (1)
Haemophilia B and other bleeding disorders (2000) (1)
Genetic Background in Patients with Severe Factor XIII A-Subunit Deficiency Treated with Recombinant FXIII (2012) (1)
FISH for Carrier Detection of large Deletions in the Factor VIII Gene (2004) (1)
Platelet-Dependent Thrombin Generation Induced By ADP or Activated Factor X Does Not Contribute to Increased In Vivo Thrombin Formation in Myeloproliferative Neoplasms (2018) (1)
Ex Vivo Modeling of the PC (Protein C) Pathway Using Endothelial Cells and Plasma: A Personalized Approach (2022) (1)
GGCX variants leading to biallelic deficiency to γ‐carboxylate GRP cause skin laxity in VKCFD1 patients (2021) (1)
Recommendations for Thrombosis Prophylaxis in SARS-CoV-2 (COVID-19) (2020) (1)
Case Report of an Acquired Inhibitor Against Factor XIII (2008) (1)
[Gathering and evaluation of phenotype data of haemophilia A patients for correlation with genotype data]. (2003) (1)
Individualised Prophylaxis with Recombinant Factor IX FC Fusion Protein (RFIXFC) in Adults/Adolescents With Haemophilia B: Updated Interim Results of the B-YOND Extension Study (2017) (1)
Molecular Genetics Analysis of Von Williebrand Disease: Studies in Cohort Pakistani Patients (2015) (1)
New insight into the function of VKORC1L1 (2010) (1)
Molecular genetic background of haemophilia A patients with discrepancy between one-stage and two-stage factor VIII assays (2010) (1)
Lack of Factor VIII Expression Represents a Novel Mechanism Leading to Hemophilia A (2006) (1)
Simultaneous Bilateral Total Knee Arthroplasty in Hemophilic Arthopathy (2007) (1)
Von Willebrand factor propeptide and pathophysiological mechanisms in European and Iranian patients with type 3 von Willebrand disease enrolled in the 3WINTERS‐IPS study (2022) (1)
A novel fibrinogen γ chain frameshift deletion (c.637delT) in a patient with hypodysfibrinogenemia associated with thrombosis (2015) (1)
An in silico and in vitro approach to elucidate the impact of residues flanking the cleavage scissile bonds of FVIII (2017) (1)
Extended-Interval Prophylaxis with rFIXFc in Adults and Adolescents with Hemophilia B: Interim Results of the B-YOND Extension Study (2015) (1)
Natural History Of Hemophilic Joint Disease Using Sensitive Imaging With Magnetic Resonance Imaging (MRI) (2013) (1)
Real-world clinical experience of extended half-life recombinant factor VIII Fc fusion protein (rFVIIIFc) in comparison to conventional factor products in patients with severe hemophilia A (2021) (1)
Variation in Plasma Levels of Apixaban and Rivaroxaban in Clinical Routine Treatment of Venous Thromboembolism (2022) (1)
GGCX variants leading to biallelic deficiency to γ-carboxylate GRP cause skin laxity in VKCFD1 patients (2021) (1)
Real-World Effectiveness and Safety of BAY 94-9027 (Damoctocog Alfa Pegol) in Previously Treated Patients with Hemophilia A (HEM-POWR): Online Patient Portal and LIFE-ACTIVE Sub-Study (2019) (1)
THROMBOSIS AND HEMOSTASIS Human VKORC 1 mutations cause variable degrees of 4-hydroxycoumarin resistance and affect putative warfarin binding interfaces (2013) (1)
Rapid and Sensitive Detection of Heterozygous Deletions of one or more Exons in Hemophilia A Females by Multiplex PCR and DHPLC Technique (2007) (1)
Effectiveness and Safety Outcomes in Patients with Hemophilia a Receiving Antihemophilic Factor (Recombinant) for at Least 5 Years in a Real-World Setting: 6-Year Interim Analysis of the Ahead International and German Studies (2020) (1)
Successful Embryo Transfer and Pregnancy with Donated Egg in a Female with Severe FXIII Deficiency and Climacterium Praecox (2020) (1)
Inhibitors in PTP'S: A Retrospective Study in Germany (2006) (1)
PC Deficiency Testing: Thrombin-Thrombomodulin as PC Activator and Aptamer-Based Enzyme Capturing Increase Diagnostic Accuracy (2021) (1)
Epitope mapping of anti-FVIII antibodies from different sources with cellulose-bound peptide libraries (1999) (1)
Genetic Basis for Inhibitor Development (2011) (1)
[Algorithm for the treatment of the haemophilic arthropathia of the upper ankle joint]. (2010) (1)
Type 2B von Willebrand Disease: Early Manifestation as Neonatal Thrombocytopenia. (2021) (1)
Immune Tolerance Induction (ITI) with a pdFVIII/VWF Concentrate (octanate) in 100 Patients in the Observational ITI (ObsITI) Study (2022) (1)
Striving for a Bleed Free World - An Interim Analysis from the AHEAD Study (2016) (1)
Mutations in the VKORC1 Gene Cause Warfarin Resistance, Warfarin Sensitivity and Combined Deficiency of Vitamin K Dependent Coagulation Factors. (2004) (1)
A Bladder Hematoma Mimicking a Tumor in a Newborn with Severe Hemophilia A (2015) (1)
Novel and Recurrent Mutations in the Gamma-Glutamyl Carboxylase (GGCX) Gene (2005) (1)
Rescue and Primary ITI in Children and Adults with a Single FVIII/VWF Product (2012) (1)
Investigation of Underlying Reasons of Factor VIII Deficiency in Hemophilia A Patients with Undetectable Mutations in the F8 Gene (2006) (1)
Glycophorin A-based exclusion of red blood cells for flow cytometric analysis of platelet glycoprotein expression in citrated whole blood (2020) (1)
octanate®: over 20 years of clinical experience in overcoming challenges in haemophilia A treatment (2020) (1)
Bleeding Symptoms in Carriers of Hemophilia A — Association to the Factor VIII Gene Mutation? (2004) (1)
11 novel Mutations in the Factor VIII encoding Gene lead to severe or moderate Hemophilia A (2003) (1)
Neoplasm-induced bleeding in inherited, heterozygous FXIII-A deficiency (2015) (1)
Consumption Of FVIII Concentrate During On-Demand and Prophylactic Treatment With Human-cl rhFVIII In Prospective Clinical Studies In Adult Patients With Severe Hemophilia A (2013) (1)
Long‐term surveillance for human anti‐murine antibodies of a group of haemophiliacs treated only with immunoaffinity‐purified FVIII concentrates (1995) (1)
[Prophylactic factor substitution in severe haemophilia A. Economic assessment in adult patients]. (2014) (1)
New Data on the Safety and Efficacy of Recombinant FXIII in Patients with Congenital FXIII A-Subunit Deficiency (2014) (1)
Safety of intramuscular COVID‐19 vaccination in patients with haemophilia (2022) (1)
Inhibitor development and management in three non-severe haemophilia A patients with T295A variant (2014) (1)
Eahad-DB: a combined coagulation factor variant databases resource for the clinical and scientificcommunities (2015) (1)
First Case of Compound Heterozygosity in the Gamma- Glutamyl Carboxylase Gene Causing Combined Deficiency of all Vitamin K-Dependent Blood Coagulation Factors (2004) (1)
Molecular Genetic Analysis in Patients with Inherited Factor V Deficiency (2007) (0)
Abstracts of the World Federation of Hemophilia, 13(th) International Musculoskeletal 2013 Congress, April 18-21, 2013, Chicago, USA. (2013) (0)
Basel , Switzerland Calcium binding sites of coagulation factor XIII ( FXIII ) A subunit and their functional relevance to the activation of FXIII A subunit (2017) (0)
Mutation and Inhibitor Incidence in a Defined Cohort of Severely Affected Haemophilia A Patients Born After 1977 (2000) (0)
PLGA based nanoparticles as protein carriers: Radiolabeled protein delivery system (2017) (0)
Transient elastography (FibroScan®) in patients with chronic hepatitis C infection and haemophilia A (2007) (0)
VKORC1 (vitamin K epoxide recycling polypeptide), a therapeutic target for coumarin and derivatives thereof (2004) (0)
[Hamburg Hemophilia Symposium 2012]. (2013) (0)
Evaluation of Denaturing High Performance Liquid Chromatography (DHPLC) in the Analysis of Hemophilia A (2002) (0)
Denaturing High Performance Liquid Chromatography Represents an Efficient Technique for Detection of Heterozygous Large Deletions in Antithrombin Gene (2006) (0)
Mutations in the Factor VIII C1 domain reducing Factor VIII binding to von Willebrand Factor and resulting in mild/moderate haemophilia A do not prevent a clinically useful response to DDAVP (2001) (0)
Comprehensive Proﬁling of Blood Coagulation and Fibrinolysis Marker Reveals Elevated Plasmin-Antiplasmin Complexes in Parkinson’s Disease (2021) (0)
Intrinsic difference in cellular response between full-length and B-domain deleted FVIII HEK293 secreting cells: implication for gene therapy (2023) (0)
Mutation Analysis in Hereditary Angioedema Identifies Patients at Risk for Developing Acute and Life Threatening Edema (2006) (0)
Elucidation of Gross Genomic Rearrangements Involving Large Deletions in the Clotting Factor VIII Gene (2008) (0)
Direct andIndirect Estimation oftheSexRatioofMutation Frequencies inHemophilia A (1993) (0)
Circulating Plasminogen Activator Inhibitor-1 (PAI-1) Is Reduced By In Vivo Thrombin Generation and Subsequent Formation of Activated Protein C (APC) (2019) (0)
VKORC1-dependent pharmacokinetics of intravenous and oral phylloquinone (vitamin K1) mixed micelles formulation (2012) (0)
Analysis of the Biological Importance of the VKORC1 Gene via Knock-Out Mice (2008) (0)
Ahead Study: A 3 Year Follow-up of 522 Severe and Moderate Hemophilia a Patients (2016) (0)
Abstract (2003) (0)
PHAGOCYTES, GRANULOCYTES, AND MYELOPOIESIS Increased circulating levels of neurotrophins and elevated expression of their high-af ﬁ nity receptors on skin and gut mast cells in mastocytosis (2013) (0)
Human-Cl Rhfviii Effectively and Safely Prevents Bleeding Episodes in Previously Treated Adult Patients with Severe Haemophilia A (2012) (0)
SNP Map of the Protein C Gene (2005) (0)
Adenovirus-mediated regulatable Expression of human Factor IX in vitro and in vivo (2003) (0)
Peripheral tolerance and lymphocyte anergy (PP-072) (2010) (0)
Inhibitor Development in Previously Untreated Patients with Hemophilia A and B: A Prospective 23-Year Follow-Up (2001) (0)
Acute Care and Hospitalizations (2016) (0)
M-FPMED01-005 (298) | Prevalence of mild factor XIII deficiencyphenotype: Current update to the WFH sponsored CRGP study (2018) (0)
Contents Vol. 102, 2012 (2012) (0)
Maximum foot pressure during gait in patients with severe haemophilia: A controlled cross-sectional study (2022) (0)
Pharmacogenetics of Oral Anticoagulation - VKORC1-Haplotypes Determine the Inter-Individual and Inter-Ethnical Variability. (2006) (0)
Evidence of Thrombin-Independent Generation of Activated Protein C (2016) (0)
Identification of Novel Mutations with Molecular Modelling of Missense Mutations of Congenital Afibrinogenemia Patients in Pakistan (2015) (0)
Factor VIII light chain mutations and cysteine substitutions predispose for inhibitor development in mild and moderate haemophilia A: first results from the INSIGHT study (2010) (0)
Contents Vol. 121, 2008 (2008) (0)
Report on Experiences with Two Recombinant Factor VIII Concentrates: Kogenate® (Bayer) and Recombinate® (Baxter) (1995) (0)
On the Molecular Basis of Warfarin Resistance in Rats (2007) (0)
Factor VIII Inhibitors in Haemophilia A Patients after Continuous Infusion of Factor VIII Concentrates. (2004) (0)
Spleen Size and Thrombocytopenia After Transcatheter Aortic Valve Implantation. (2021) (0)
Insights into the Molecular Genetic of Hemophilia A and Hemophilia B: The Relevance of Genetic Testing in Routine Clinical Practice (2022) (0)
Genetic Defects in 10 Index Cases of Inherited Vitamin K Dependent Clotting Factors Deficiency (2015) (0)
The Spectrum of Malignancies in the Era of HAART (2009) (0)
Recombinant Expression and 3D-Modelling of C1-Inhibitor Mutants (2008) (0)
Haemophilia care: Which outcomes should be determined in clinical routine care and are adequate for access requirements (2016) (0)
Haemophilia (A) therapeutics: from plasma-derived products to personalized cell-based therapies (2014) (0)
Long-range PCR screening for large rearrangements in the FVIII gene in patients without detectable mutations in the coding sequence (2010) (0)
The Variable Clinical Expressivity of Factor V Leiden, but Not of Prothrombin G20210A, Correlates with the Extent of the APC Response to In Vivo Thrombin Formation (2018) (0)
Osteoporosis Remains Constant in Patients with Hemophilia—Long-Term Course in Consideration of Comorbidities (2022) (0)
VKORC1 polypeptide recycling vitamin k-epoxide, a therapeutic target of coumarin and its derivatives. (2004) (0)
Treatment of Haemophilia a (HA) Patients with Inhibitors: Immune Tolerance Induction with a Single Factor VIII/Von Willebrand Factor Concentrate in an Observational Immune Tolerance Induction Study (ObsITI) (2018) (0)
[Homo erectus haemophilus - the haemophilic arthropathy of the leg]. (2011) (0)
Intrauterine Subdural Hemorrhage Associated with Profound Deficiency of the Vitamin K Dependent Clotting Factors in an Infant Homozygous for a Common Polymorphism in the Vitamin K Epoxide Reductase Complex 1 (VKORC1) Promoter. (2007) (0)
Philadelphia-positive acute lymphoblastic leukemia ( Ph imatinib-based therapy and give rise to relapse in patients with de novo Kinase domain mutations of BCR-ABL frequently precede (2007) (0)
Investigation of Differential Interaction between GGCX and VKD Clotting Factors by an In Silico Approach (2022) (0)
Pseudo tumours in haemophilia patients (2009) (0)
Creation and Characterization of a Knock-Out Mouse for the VKORC1L1-Gene (2008) (0)
NQO1 – A bypass of the vitamin K-cycle? (2010) (0)
Mutation Analysis of the C1 Inhibitor Gene (2005) (0)
Recruitment update of AHEAD (2013) (0)
Therapy-resistant haemarthros in a patient with factor VIII inhibitor: successful treatment with recombinant factor VIIa (1999) (0)
Von Willebrand Factor antigen and age explain variation in baseline FVIII: C among nonsevere hemophilia A patients with the same F8 genotype (Arg593Cys and Asn618Ser) (2014) (0)
Mitochondria: Emerging Consequential in Sickle Cell Disease (2023) (0)
Influence of VKORC1 Haplotypes on Cardiovascular Disease (2008) (0)
Alternative Therapy such as the Acupuncture of the Skull for Hemophilic Arthropathy (2007) (0)
THROMBOSIS AND HEMOSTASIS Factor VIII gene ( F 8 ) mutation and risk of inhibitor development in nonsevere hemophilia A (2013) (0)
Risk Factors for the Development of High-Titer Inhibitors in 260 Children with Severe Hemophilia a Born Between 1990 and 2009: The Remain Study (2016) (0)
Safety and Efficacy of Recombinant Factor XIII (FXIII) in Patients with Congenital FXIII A-Subunit Deficiency, Results from the Mentor™2 Trial (2016) (0)
99.3% of Inhibitors in Severe Hemophilia a Develop before Exposure Day 75. Time to Change Definition of Previously Treated Patients; Data from 1038 Patients with Severe Hemophilia a of the Pednet Registry (2018) (0)
Inhibitor Development after Continuous Infusion of Factor VIII: A Retrospective Study in Germany (2006) (0)
Congenital and acquired bleeding disorders: the right factor for the right patient. (2012) (0)
Emicizumab Prophylaxis in Hemophilia A with Inhibitors. (2017) (0)
Recurrent Intracranial Bleed in 3 Siblings: Short of a Shot of Vitamin K! (2020) (0)
EE120 Real-World Utilisation of Damoctocog Alfa Pegol in Adults With Haemophilia A: Second Interim Analysis of the HEM-POWR Observational Study (2022) (0)
A Homozygous Deep Intronic Variant Causes Von Willebrand Factor Deficiency and Lack of Endothelial-Specific Secretory Organelles, Weibel–Palade Bodies (2022) (0)
Patients with Familial Thrombophilia of Unknown Origin Show Low APC Response to In Vivo Thrombin Formation in Stimulated Hemostasis Activity Pattern Evaluation (SHAPE) (2019) (0)
A rare case of unprovoked venous thromboembolism manifestation in a young patient with antithrombin Type IIB deficiency combined with inferior vena cava anomaly from Lithuania (2017) (0)
Does development of cholestatic liver disease in HIV and hepatitis C coinfected hemophiliacs indicate an unfavorable prognosis (1995) (0)
Inhibitors increase the burden of disease in nonsevere haemophilia A patients - treatment strategies to obtain hemostasis (2014) (0)
Influence of G-CSF Mobilization and Liquid Storage Time on Post-Thaw Recovery of Lymphocyte Subpopulations and CD34+ Cells in Cryopreserved Apheresis Products (2015) (0)
Mutation Profiling in Congenital FXIIIA Deficiency: Detection of 6 Novel Mutations (2005) (0)
The Role of GRP and MGP in the Development of Non-Hemorrhagic VKCFD1 Phenotypes (2022) (0)
Comparison of closure time and whole blood impedance aggregometry to light transmission platelet aggregometry for the assessment of platelet response to aspirin and P2Y12 inhibitor therapies: a large-scale study in the outpatient population (2023) (0)
Epitope Mapping of FIX Inhibitors Identify Contact Residues in the Protease Domain. (2009) (0)
[Clotting factor concentrates]. (2008) (0)
Pseudo-Homozygous APC Resistance Due to Coinheritance of Heterozygous Factor V — R506Q and Type I Deficiency Associated with Thrombosis (2008) (0)
von Willebrand factor neutralizing and non-neutralizing alloantibodies in 213 subjects with type 3 von Willebrand disease enrolled in 3WINTERS-IPS. (2023) (0)
1-1 Co-activation of selected knee muscles in haemophilic patients (0)
Provision of Psychological Services in Hemophilia Treatment Postulated under the Guidelines of the WFH and the GTH—But Also in Demand? Experiences from the Hemophilia Center Bonn (2020) (0)
Duplication breakpoints in the factor VIII gene (2010) (0)
Structural Investigation of Two Novel Mutations in Coagulation Factor V by Molecular Modeling (2008) (0)
The Serpins C1-Inhibitor and Antithrombin Synergistically Regulate the Catalytic Life of Activated Factor XI in Healthy Individuals and Thrombophilic Patients (2014) (0)
Profile of Mutations Identified in the 3WINTERS-IPS Project on European & Iranian Patients with Previously Diagnosed Type 3 Von Willebrand Disease. (2018) (0)
Coagulation Factor XIII Mutation Profile: Update 2004 (2006) (0)
Lithuanian Hemophilia Register: Update 2003 (2005) (0)
First Case of Compound Heterozygous Mutations in the Kininogen Gene Causing Severe High Molecular Weight Kininogen Deficiency (2005) (0)
441 HCV CORE-SPECIFIC ADAPTIVE CD4+ REGULATORY T CELL CLONES IN CHRONIC HEPATITIS C ARE HIGHLY SUSCEPTIBLE TO INHIBITION BY RIBAVIRIN (2010) (0)
Expression of the γ-Glutamyl Carboxylase (GGCX) Containing the Arg485Pro Mutation Found in two Unrelated VKCFD1 Patients (2007) (0)
Deletion of Two Contiguous Genes, Platelet GPIbβ (Glycoprotein Ibβ) and Septin SEPT5, in a Boy with Bernard-Soulier Syndrome and Developmental Delay: A Possible New Contiguous Gene Syndrome. (2006) (0)
Untreated Bleeds May Be Historically Under-Reported and More Prevalent in People with Hemophilia A with Inhibitors: An Examination of Bleed Data from a Prospective, Non-Interventional Study (2018) (0)
Analysis of Factor VIII RNA from Hemophilia A Patients with no Detectable Mutation in the Coding Regions (2004) (0)
Determinants of successful immune tolerance induction in hemophilia A: systematic review and meta-analysis (2022) (0)
Effects of Pathogen Inactivation Using Amotosalen-UVA on Coagulation Parameters in Apheresis and Whole Blood Derived Frozen Plasma in a Large Blood Bank Setting. (2006) (0)
Annual Meeting of the Society of Thrombosis and Hemostasis Research 15-18 February 2017 Basel , Switzerland rhADAMTS 13 treatment improves ventricular remodeling and functionality after cardiac injury in mice (2017) (0)
HLA Profile in Acquired Hemophilia (2005) (0)
Peripheral Blood Leukocyte DNA Aberrant Methylation in Gastric Cancer Patients (2013) (0)
Evaluation of the protein C pathway in critically ill patients with severe COVID-19 as compared to bacterial sepsis (2023) (0)
Pain in patients with hereditary bleeding disorders: evaluation of a survey among people affected in Germany (2023) (0)
S2083 Correlation of TRANSIENT ELASTOGRAPHY with APRI and Fib-4 in a Cohort of Patients with Congenital Bleeding Disorders and HCV Infection or HIV/HCV Co-Infection (2009) (0)
Impaired in vivo activated protein C response rates indicate a thrombophilic phenotype in inherited thrombophilia (2022) (0)
Monitoring of Emicizumab using a Two-stage chromogenic tenase platform: assay Development and Validation (2019) (0)
Recombinant porcine factor VIII corrects thrombin generation in vitro in plasma from patients with congenital hemophilia A and inhibitors (2022) (0)
Response to TLR7 Ligation Support Th17 Cell Effector Function in Human Plasmacytoid Dendritic Cells (2009) (0)
Species-Specific Variation of VKORC1-Activity and Resistance to Warfarin (2007) (0)
Localization and Characterization of Mutations Within the Factor VIII Gene in a Cohort of 212 Patients with Hemophilia A (2001) (0)
Development of Antidrug Inhibitory Antibodies against Polyethylene Glycol after Treatment with PEGylated Factor VIII Therapeutic (2022) (0)
Immune Tolerance Induction and Immunosuppression in a 25-Year-Old Patient with Inherited Severe Factor IX Deficiency and Inhibitor: 1-Year Follow-Up (2022) (0)
γA1a82Gly Represents a Common Fibrinogen Chain Variant in Caucasians (2006) (0)
Erratum to: Prophylaxis and quality of life in patients with hemophilia A during routine treatment with ADVATE [antihemophilic factor (recombinant), plasma/albumin-free method] in Germany: a subgroup analysis of the ADVATE PASS post-approval, non-interventional study (2013) (0)
The Mystery of Antibodies Against Polyethylene Glycol (PEG) - What do we Know? (2016) (0)
Patient-reported symptoms to predict intra-articular location of joint bleeds (2023) (0)
Nuwiq Dosing and Outcomes in the Management of Women/Girls with Haemophilia a Needing FVIII Treatment for Surgery - an International, Open-Label, Non-Controlled Study (NuDIMENSION) (2022) (0)
Emicizumab prophylaxis for the treatment of people with moderate or mild Hemophilia A without Factor VIII inhibitors: results from the primary analysis of the HAVEN 6 study (2023) (0)
HEM-POWR study: Subgroup analysis evaluating the real-world effectiveness and safety of damoctocog alfa pegol in previously treated patients with haemophilia A in Germany (2023) (0)
Contents Vol. 77, 2008 (2008) (0)
Optimization and evaluation of a two-stage chromogenic assay procedure for measurement of emicizumab plasma levels (2022) (0)
Safety and efficacy of recombinant Factor IX fusion protein (rIX-FP) in previously untreated patients with haemophilia B (2023) (0)
Heatmap showing p values and significant Spearman correlation coefficient (ρ) between methylation levels of different CpGs in paired peripheral blood and ductal adenocarcinoma tissues (p values of >0.05 are in white, the shown ρ-values are corresponding to p values <0.05). (2012) (0)
In Contrast to Full-Length Factor VIII, the Calnexin (ER Chaperone) and LMAN1 (ERGIC transporter) Knockouts Have Minimal Effect on the Secretion of B-Domain-Deleted Factor VIII: Implication for Gene Therapy (2022) (0)
Updated interim safety analysis of the real-world HEM-POWR study evaluating damoctocog alfa pegol in previously treated patients with haemophilia A (2023) (0)
Influenza infections destabilize established immune tolerance in HemA mice (2023) (0)
Methylation Profile of Adult and Fetal FVIII Secreting Endothelial Cells in Comparison to other Endothelial Cells (2019) (0)
Assay for ADAMTS-13 Activity with Flow Cytometric Readout (2022) (0)
Importance of Genetic Testing in Congenital Factor VII Deficiency (2022) (0)
Cardiovascular interventions in patients with haemophilia and severe von Willebrand disease (2008) (0)
An improved understanding of native coagulation factor XIII complex structure using cryo-EM (2023) (0)
Baseline Data from a 24-month Prospective, Non-interventional, Multicentre Study in Germany to Evaluate the Real-world Usage and Effectiveness of rFVIIIFc and rFIXFc in Patients with Haemophilia A or B (PREVENT) (2019) (0)
Correlation between coagulation factor residual activities and detection rate of diseasecausing variants in Rare Bleeding Disorders (2023) (0)
EMIIL - Non-interventional study to investigate the effectiveness of Emicizumab under real-world conditions in pediatric, adolescent, adult and elderly patients with hemophilia A (PwHA) with and without FVIII inhibitors: an interim analysis (2023) (0)
Clinical experience of switching patients with severe hemophilia to rVIII-SingleChain or rIX-FP (2022) (0)
In-vitro and In-silico characterization of a pathogenic variant in integrin β3 associated with hereditary macrothrombocytopenia (2023) (0)
Revealing Pathogenic Molecular Mechanism in a Type 3 von Willebrand Disease Patient by Inspecting VWF Gene Whole Intronic Region and Study of The Patient-Derived Endothelial Cells (2022) (0)
Haemophilia A Prophylaxis with FVIII in Real-life: Snapshot Analysis on the Observational Study “Prevention of Bleeding in Haemophilia A by Prophylactic Treatment with Octanate®, Wilate® or Nuwiq® - NIS Previq” (2019) (0)
Gene therapy of Hemophilia: Recommendations from the German, Austrian, and Swiss Society for Thrombosis and Haemostasis Research (GTH) (2023) (0)
A Retrospective Study on the Development of Inhibitors after Continuous Infusion of Factor VIII (2004) (0)
HIV-associated microbial translocation may affect cytokine production of CD56bright NK cells via stimulation of monocytes. (2022) (0)
Emicizumab Prophylaxis for the Treatment of Infants with Severe Hemophilia A without Factor VIII Inhibitors: Results from the Interim Analysis of the HAVEN 7 Study (2022) (0)
Interim Subgroup Analysis of the Effectiveness and Safety of Damoctocog Alfa Pegol Prophylaxis in Previously Treated Patients with Hemophilia A Treated Every 5 or Every 7 Days: Results from the Real-World Observational HEM-POWR Study (2022) (0)
Anti-drug antibodies against the PEG moiety inhibit the procoagulant activity of therapeutic PEGylated FVIII. (2023) (0)
Expression Studies of Recombinant FVIII Proteins Exhibiting Mutations in the B-Domain (2005) (0)
Blood Coagulation , Fibrinolysis and Cellular Haemostasis Molecular basis of antithrombin deficiency (2018) (0)
This information is current as in Human B Cells and Monocytes RII ε Distinct Expression and Function of Fc Garbi (2017) (0)
Founder Effect of the Factor-IX-Propeptide-Val-10 Variant Is Responsible for Most Marcumar-lnduced Severe Haemophilia B Cases During Oral Anticoagulant Therapy — Consequences for Monitoring (1999) (0)
Recombinant expression of wildtype and mutated γ-glutamyl carboxylase (2008) (0)
Molecular Characterization of F8 Secreting Cell (2015) (0)
[HIV-associated parotid cysts]. (1994) (0)
Establishment and specification analysis of LSEC-like endothelial cells for the detection of endogenous FVIII (2023) (0)
Novel Gamma-Glutamyl Carboxylase Mutation Causing Hemorrhagic and Non-Hemorrhagic VKCFD1 Phenotypes (2022) (0)
Inversions at Xq28 Causing Hemophilia A Are Associated with Specific (2020) (0)
Clustering of Bleeding Symptoms in Patients Previously Diagnosed As Type 3 Von Willebrand Disease: Results from a Large Cohort of Type 3 Von Willebrand Disease (the 3Winters-Ips Project) (2018) (0)
interfaces 4-hydroxycoumarin resistance and affect putative warfarin binding Human VKORC1 mutations cause variable degrees of (2013) (0)
Increased Prevalence of Elevated D-Dimer Levels in Patients on Direct Oral Anticoagulants: Results of a Large Retrospective Study (2022) (0)
Types and Sub Types of Von Willebrand Disease Classified on the Basis of Multimer Analysis (2015) (0)
Alpha-2 Macroglobulin: A Novel Putative Interacting Partner of FXIII/FXIIIB Subunit? (2020) (0)
Functional Promoter Polymorphism in the VKORC1 Gene is no Major Genetic Determinant for Vitamin K Dependent Coagulation Factor Activity (2008) (0)
Emicizumab Prophylaxis in Persons with Hemophilia A, Aged ≥50 Years, with Comorbidities - Pooled Data from Four Phase III Studies (HAVEN 1, 3, and 4, and STASEY) (2021) (0)
Advances in HIV-PCR in respect to the different fields of diagnosis (1994) (0)
A snapshot analysis of a prospective, non-interventional study to evaluate real-life prophylactic treatment schedules of factor VIII concentrates (2023) (0)
624 HEPATITIS C VIRUS INFECTION ALTERS SERUM LEVELS OF THE MAJOR TYPE III INTERFERON IL-29 (2008) (0)
Structural Characterization of Factor VIII B Domain to Generate an All Atom Full-Length Structure of the Coagulation Factor VIII Protein (2022) (0)
Detection of parvovirus B19 specific antibodies and DNa in sera of hemophiliacs (1994) (0)
Impact of Novel Missense Mutation (p. Arg510Cys) in the FGA Gene Resulting in Dysfibrinogenemia (2020) (0)
as a somatic mosaicism De novo factor VIII gene intron 22 inversion in a female carrier presents (2013) (0)
Stratifying Cumulus Cell Samples Based on Molecular Profiling to Help Resolve Biomarker Discrepancies and to Predict Oocyte Developmental Competence (2021) (0)
Clinical presentation of inhibitor development in non-severe hemophilia A: Half of patients have high titer inhibitors and present with bleeding complications (2014) (0)
A Polycistronic Mammalian Vector/Expression System to Establish the Causality of FXIII Heterozygous Variant Species (2022) (0)
XIII deficiency Recombinant factor XIII: a safe, and novel treatment for congenital factor (2012) (0)
GENETIC BASIS OF ACQUIRED HAEMOPHILIA (2007) (0)
Gene Therapy for Hemophilia-Opportunities and Risks. (2022) (0)
LumiTope: Toward Improving the Performance of Identification of Antifactor VIII Antibodies in Congenital and Acquired Hemophilia A (2020) (0)
Region critical for monocytotropism is concerned in diversification of HIV-1 strains derived from a unique infectious source (1994) (0)
Immunogenicity of Two Plasma-Derived FVIII Products and Simoctocog Alfa in Previously Untreated Patients According to F8 Mutation Type (2018) (0)
Genetics of warfarin resistance Two enzymes essential for the vitamin K cycle (2017) (0)
Variability in Clinical Phenotype of Hemophilia : Role of the F 8 / F 9 Genotype (2013) (0)
Elevated plasminogen activator inhibitor-1 is not associated with impaired plasmin formation and thrombotic risk after low-grade coagulation activation in vivo (2023) (0)
F8a, F8b and F8c expression and its association with 3 SNPs within the F8 gene in healthy controls and HA patients with no mutation (2010) (0)
Molecular Genetic Analysis in Patients with Inherited Thrombophilia and Antithrombin, Protein C or Protein S Deficiency (2005) (0)
nonsevere hemophilia A ) mutation and risk of inhibitor development in F8 Factor VIII gene ( (2014) (0)
Hepatitis C Virus Infektion verändert Serumspiegel des Typ III Interferons IL-29 (2008) (0)
Experiences in Routine Genetic Analysis of Hereditary Hemorrhagic, Thrombotic, and Platelet Disorders. (2022) (0)
Longterm follow-up of a women with an acquired inhibitor against factor VIII (2010) (0)
Distribution of F8 Gene Mutations in 81 Inhibitor-Free, Severe Hemophilia a Patients with Full Exposure to FVIII (2014) (0)
Perception of Actual Factor Concentrates and Expectations Towards Future Treatment with New Long-Lasting Products - Results of a Survey Among Haemophilia Patients in Germany (2015) (0)
Preanalytical quenching of FVIII using FVIII-inhibitors improves the specificity of functional emicizumab testing (2023) (0)
Localization and characterization of human anti-factor VIII antibody epitopes by screening cellulose-bound peptide libraries (2000) (0)
Analyzing secretion-based patterns of the heterozygous species of coagulation Factor XIII B cysteine mutations reported from mild FXIII deficiency using confocal microscopy (2023) (0)
Association analysis between DNA methylation from total blood and polymorphisms in DNA methyltransferase (DNMT) genes in healthy individuals: A tendency toward higher methylation levels in males (2008) (0)
Erratum (2020) (0)
Switching to rVIII-SingleChain Ensures Bleeding Protection and may Reduce Injection Frequency or Consumption in Hemophilia A Patients: Real-world Clinical Experience in Adults/Adolescents and Pediatric Patients (2019) (0)
A Cross-sectional Analysis of Treatment in PUPs in 2021 in Germany – First Data from the GEPHARD Study Group (2021) (0)
VKORC1 (vitamin K epoxide tilbageføringspolypeptid), a therapeutic target of coumarin and its derivatives (2004) (0)
Emicizumab dose up‐titration in case of suboptimal bleeding control in people with haemophilia A (2022) (0)
Haemophilia A in a Female Due to Compound Heterozygosity of a Maternally Inherited Point Mutation and a Paternally De Novo Large Deletion Within the Factor VIII Gene (2000) (0)
Frequency and Inhibitor Risk of the Intron-1-Inversion Mutation in the German Hemophilia Population (2005) (0)
AHEAD International and German Studies: Effectiveness, Safety, and Quality of Life Outcomes in Patients with Hemophilia A Treated with Antihemophilic Factor (Recombinant) in a Real-World Setting Over 5 Years (2020) (0)
Various Missense Mutations in the Vitamin K Epoxide Reductase Complex Subunit 1 (VKORC1) Cause Hereditary Coumarin Resistance (2007) (0)
Real life management of children with severe hemophilia A and inhibitors: First results of the remain study (2016) (0)
In Vivo-Assay for Warfarin-Resistance by Coexpression of VKORC1 and Vitamin K-Dependent Coagulation Factors (2007) (0)
882 SELECTIVE INDUCTION OF ADAPTIVE REGULATROY T-CELLS IN CHRONIC HEPATITIS C (2009) (0)
Expectations and Concerns Towards New Extended Half-Life (EHL) Products - Results of Surveys Among Haemophilia Patients from the Dach Region (2016) (0)
Missense Mutations at ALA-10 in the Factor IX Propeptide: A Novel Mechanism for Severe Bleeding During Oral Anticoagulant Therapy (1998) (0)
Bleeding Tendency in Factor XI Deficiency: Report on two Families and the Detection of a Novel Mutation within the Factor XI Gene (2005) (0)
Antioxidant properties of VKORC1L1 (2009) (0)
Determination of ɣ-carboxylation Pattern of Different Vitamin K Dependent Proteins with Respect to VKCFD1 Phenotype (2019) (0)
Coincidence of 2 Severe Chronic Diseases: Presymptomatic Diagnosis of Wilson Disease in A Boy With Severe Haemophilia A (2013) (0)
Practical Utilisation of Octapharma FVIII Concentrates in Previously Untreated and Minimally Treated Haemophilia a Patients Entering Routine Clinical Treatment with Nuwiq®, Octanate® or Wilate® — the Protect-NOW Study (2018) (0)
Inhibitor development and FVIII gene mutation analysis in a pediatric cohort treated with sucrose formulated, full‐length recombinant Factor VIII (2002) (0)
Dynamic of Thrombin Generation in Patients with Severe Hemophilia A (2008) (0)
How to avoid being eaten: a lymphoma's defense (2017) (0)
Investigating the interaction of circulating von Willebrand factor with polymorphonuclear leukocytes ex vivo (2023) (0)
Expression Analysis of C1-Inhibitor Mutants Confirms Causality of Missense Mutations for Hereditary Angioedema (2007) (0)
Subject Index Vol. 77, 2008 (2008) (0)
Subject Index Vol. 23, 1996 (1996) (0)
De Novo Factor VIII Intron 22 Inversion in Early Embryogenesis Leads to a Mosaic Genotype in Leukocyte and Fibroblast Cells (2000) (0)
Erratum: A Cross-sectional Analysis of Treatment in PUPs in 2021 in Germany – First Data from the GEPHARD Study Group (2021) (0)
State-of-the-Art in Hämostaseologie (2011) (0)
Congenital Deficiency of Vitamin K Dependent Coagulation Factors in Two Families: Evidence for a Defective Vitamin K-Epoxide-Reductase Complex (2001) (0)
Correction: Methylation at Global LINE-1 Repeats in Human Blood Are Affected by Gender but Not by Age or Natural Hormone Cycles (2015) (0)
Design of the HEM-POWR study: a prospective, observational study of real-world treatment with damoctocog alfa pegol in patients with haemophilia A (2021) (0)
Mutation Type Dependent Inhibitor Risk — a Single Center Study on 432 Patients with Severe Hemophilia A (2006) (0)
Suspected vitamin K-dependent coagulation factor deficiency in pregnancy: A case report (2022) (0)
UNCHANGED PHARMACOKINETICS OF AZIDOTHYMIDIN (AZT) IN HIV-INFECTED HEMOPHILIACS WITH CONCOMITANT CHRONIC HEPATITIS (1994) (0)
Establishment of an International Registry of Patients with Congenital FXIII Deficiency (2007) (0)
Quantitative expression analysis of the F8 mRNA in haemophilia A patients with no detectable mutation in the F8 gene (2009) (0)
Five Novel Mutations in F13B Gene Resulting in Mild FXIII Deficiency (2007) (0)
Genetic landscape in coagulation factor XIII associated defects – Advances in coagulation and beyond (2022) (0)
High Levels of Human Factor IX Transgene Expression in Mice Increase Blood Procoagulant Activity (2008) (0)
Novel Variants in VKORC1 — the Target Protein of Cumarin-Type Anticoagulants — in Rodents from Warfarin-Resistance Areas in Europe, Asia and America (2008) (0)
VKORC1 (vitamin K epoxide feed back polypeptide), a therapeutic target of coumarin and its derivatives (2004) (0)
PSEUDO-HOMOZYGOUS APC RESISTANCE DUE TO COINHERITANCE OF HETEROZYGOUS FACTOR V-R506Q AND FV TYPE I DEFICIENCY (2007) (0)
Safety and Efficacy of Turoctocog Alfa in Prevention and on-Demand Treatment of Bleeding Episodes in Patients with Hemophilia A (2016) (0)
Resistance to Coumarin in a 55-year-old Patient with Chronic Arrhythmia (2005) (0)
Molecular Profiling of Fetal and Adult Liver Sinusoidal Endothelial Cells: A F8 Secreting Cell (2020) (0)
Expressing Recombinant Coagulation Factors in Yeast and Insect Cells (2005) (0)
Coexpression of VKORC1 and coagulation factor IX (2010) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Johannes Oldenburg?

Johannes Oldenburg is affiliated with the following schools:

University of Lübeck
University of Göttingen
Johns Hopkins University
University of Würzburg
University of Bonn

Johannes Oldenburg's Academic­Influence.com Rankings

Why Is Johannes Oldenburg Influential?

Johannes Oldenburg's Published Works

Published Works

What Schools Are Affiliated With Johannes Oldenburg?

Johannes Oldenburg's AcademicInfluence.com Rankings